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Chapter 1
Introduction
Drug addiction is a disease causing major social and health problems in human society and
many efforts have been made to understand the underlying biological mechanisms. It is com-
monly referred to as a chronically relapsing disorder, which is characterized by three major
aspects: (A) the compulsion to seek and take the drug combined with (B) a loss of control in
limiting intake and (C) the emergence of a negative emotional state, when access to the drug
is prevented (KOOB AND LE MOAL, 2005). The behavioral changes that lead to addiction
develop gradually and progressively due to repeated exposure to a drug of abuse and can persist
for even long periods after abstinence (NESTLER, 2004B). A focus of research in this field is
to understand the mechanisms underlying the transition from controlled occasional drug use to
the uncontrolled intake characteristic for addiction (KOOB AND LE MOAL, 2008). The initial
drive for drug consumption is its ability to produce pleasurable effects (FELTENSTEIN AND
SEE, 2008). Such a stimulus that the brain interprets as intrinsically positive or as something
to be attained is called reward (CAMÍ AND FARRÉ, 2003). Basically all drugs of abuse interact
with the brain reward system (KOOB, 1992; FELTENSTEIN AND SEE, 2008). The brain re-
ward system is defined as brain circuits involved in positive reinforcement in combination with
positive hedonic valence (KOOB AND LE MOAL, 2008). Today, addiction theories assume
that prolonged drug use leads to a state of dysregulation of the brain reward system result-
ing in compulsive drug use (FELTENSTEIN AND SEE, 2008; KOOB AND LE MOAL, 2008).
The mesocorticolimbic dopamine system plays a key role in reward. Basically, all addictive
drugs enhance mesocorticolimbic dopamine activity (KOOB, 1992; FELTENSTEIN AND SEE,
2008), although their interactions with this system occur at different levels (CAMÍ AND FARRÉ,
2003). The dopamine system consists of projections from cell bodies in the ventral tegmental
area (VTA) to limbic structures (mesolimbic pathway) and to cortical areas (mesocortical path-
way). These circuits operate in parallel, but may have somewhat different roles in the addiction
process (CAMÍ AND FARRÉ, 2003). The mesolimbic pathway is involved in the acute rein-
forcing effects of drugs of abuse, for example rewarding stimuli lead to dopamine release in the
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nucleus accumbens (NAc) (DI CHIARA, 2002; KOOB, 1992; FELTENSTEIN AND SEE, 2008).
Besides dopamine, other transmitter systems have been identified as playing a role in acute rein-
forcement and reward, including the endogenous opioid system. Opioid signaling can modulate
neurotransmission of γ-aminobutyric acid (GABA) and therefore influence the activation of the
mesolimbic dopamine system (WILLIAMS ET AL., 2001; BERRENDERO ET AL., 2005). In
addition, an important role for the opioid system independent of dopamine signalling has been
proposed (KOOB, 1992) suggesting a general implication for this system in drug addiction.
1.1 The opioid system
Drugs derived from the poppy plant Papaver somniferum and structurally related compounds
are collectively referred to as opiates. Their use for medical purposes has a long tradition, as
opiates are well known for their pain relieving and rewarding properties. Early efforts to un-
derstand the endogenous targets of opiates led to the identification of the specific receptor sites
in the brain and the subsequent cloning of µ-, δ- and κ-opioid receptors (PERT AND SNYDER,
1973; KIEFFER AND GAVERIAUX-RUFF, 2002). These receptors belong to the superfamily
of G-protein-coupled receptors (GPCRs). Via coupling to Gi- or Go-proteins, they can activate
a class of inwardly rectifying potassium channels, inhibit voltage-sensitive calcium channels
and adenylyl cyclase. In addition, they activate a number of kinase-mediated signaling cas-
cades (VON ZASTROW ET AL., 2003). The term opioid refers to all drugs and endogenous
substances that act via these receptors. Three types of endogenous neuropeptides bind to opi-
oid receptors, namely enkephalins, dynorphins and endorphin (GIANOULAKIS, 2004; DREWS
AND ZIMMER, 2009). These opioid peptides are produced through enzymatic processing of
precursor proteins encoded by three different genes (Penk1, Pdyn, Pomc) (AKIL ET AL., 1984).
The precursor proteins and the generated opioid peptides are illustrated in figure 1.1. The
enkephalins, Met-enkephalin, Leu-enkephalin and two further extended peptides are derived
from the preproenkephalin precursor (PENK) (WEISINGER, 1995; AKIL ET AL., 1984; GI-
ANOULAKIS, 2004). Preprodynorphin (PDYN) is processed to dynorphin A (1-8), dynorphin A
(1-17) and dynorphin B, whereas it might also yield in Leu-enkephalin through further cleavage
of dynorphin (AKIL ET AL., 1984; GIANOULAKIS, 2004; DAY ET AL., 1998; ZAMIR ET AL.,
1984). Proopiomelanocortin (POMC) is a multi-functional precursor protein that gives rise to
ß-endorphin and other non-opioid peptides such as adrenocorticothrophic hormone (ACTH), γ-
melanocyte stimulating hormone (γ-MSH) and ß-lipotropic hormone (ß-LPH) (AKIL ET AL.,
1984; GIANOULAKIS, 2004). All opioid peptides share a common N-terminal Try-Gly-Gly-
Phe-Met/Leu core (MANSOUR ET AL., 1995) that is indispensable for the activation of opioid
receptors (AKIL ET AL., 1997). The opioid peptides differ in their opioid receptor binding
affinity (Fig. 1.2). Enkephalins have a high affinity for the δ-opioid receptor and, to a lesser
extent, for µ-opioid receptors. In case of the µ-receptor, Met-enkephalin has a higher affinity
compared to Leu-enkephalin. ß-endorphin activates µ- and δ-receptors with similar affinities
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Fig. 1.1: Opioid precursor protein and their cleavage products. The opioid peptide precursor
proteins preproenkephalin (top), preprodynorphin (center) and proopiomelanocortin (bottom) are
illustrated. All precursor proteins contain a N-terminal signal peptide. Through enzymatic processing
of preproenkephalin, one copy of Leu-enkephalin ([Leu]-Enk), four copies of Met-enkephalin ([Met]-
Enk) and two further extended enkephalins can be derived. Cleavage of the preprodynorphin precursor
yield dynorphin A (dyn A) and B (dyn B), two related peptides of different lengths. Processing of the
proopiomelanocortin precursor yields in ß-endorphin (ß-end) and several non-opioid peptides such as
ACTH, γ-MSH and ß-LPH.
and the κ-receptor is nearly exclusively activated by dynorphins (MANSOUR ET AL., 1995;
CLARKE ET AL., 2003). An arginine residue in position 6 and a further extension of the dynor-
phin peptide sequence was shown to be important for κ-receptor binding (MANSOUR ET AL.,
1995). However, it was reported that dynorphins can also bind to µ- and δ-opioid receptors
with low affinities (CLARKE ET AL., 2003).
All stages of the addiction process can be monitored in animal models (see Box 1 for an
example). The analysis of addiction-related behaviors in knockout mice for all components of
the endogenous opioid system substantiated the role of this neuromodulatory transmitter sys-
tem in drug addiction. Early studies focusing on the pharmacological effects of morphine have
1.2. THE OPIOID SYSTEM AND NICOTINE ADDICTION 4
Fig. 1.2: Schematic view of the endogenous opioid receptors and their ligands. Enkephalins
and ß-endorphin activate µ- and δ-opioid receptors, whereas enkephalins have a higher affinity for
the δ-receptor. Dynorphins predominantly bind to κ-opioid receptors.
shown that in absence of µ-opioid receptors the rewarding properties were abolished. Addi-
tionally, the reinforcing properties of a wide range of other drugs, like nicotine, alcohol and
cannabis were diminished in µ-opioid receptor knockout mice (CONTET ET AL., 2004). This
indicates that µ-opioid receptor signaling influences a common molecular mechanism important
for drug reward and reinforcement. The δ-opioid receptor mediates the emotional response to
opioids (MATTHES ET AL., 1996; KIEFFER AND GAVERIAUX-RUFF, 2002). Additionally,
results on dynorphin and κ-opioid receptor knockout mice suggested that dynorphins acting
on κ-opioid receptors are involved in motivational circuits contributing to dysphoria (ZIMMER
ET AL., 2001; GHOZLAND ET AL., 2002; GAVERIAUX-RUFF AND KIEFFER, 2002). The fol-
lowing sections describe insights into the role the endogenous opioid system plays in nicotine
and alcohol addiction.
Box 1: Behavioral paradigms to study the rewarding properties of a drug:
Conditioned place-preference: Different locations are repeatedly paired with either adminis-
tration of an addictive drug or administration of vehicle. In the test phase comparison
of the time spent in the drug- or non-drug associated environment provides information
about the rewarding properties of a drug.
Operant self-administration: In this model, the animal learns to self-administer a drug by
an instrumental response contingently associated with delivery of the drug. Animals will
learn this operant behavior depending on the rewarding properties of the drug.
(BERRENDERO ET AL., 2005; MARTÍN-GARCÍA ET AL., 2009; SANCHIS-SEGURA AND
SPANAGEL, 2006)
1.2 The opioid system and nicotine addiction
Nicotine binds to the neuronal nicotinic acetylcholine receptors (nAChRs). These pentameric
ligand-gated ion channels are expressed in many brain regions including the NAc and the VTA
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(RAY ET AL., 2009; ROTH-DERI ET AL., 2008). Nicotine produces both rewarding and aver-
sive responses by modulating mesolimbic dopaminergic transmission (BERRENDERO ET AL.,
2005). Many studies demonstrated a role for the endogenous opioid system in mediating the re-
warding properties of nicotine. For example, nicotine conditioned place-preference was blocked
by naloxone, an unspecific opioid receptor antagonist (ZARRINDAST ET AL., 2003). A nor-
mally ineffective dose of morphine can produce place-preference by co-administration of an
nAChR antagonist (REZAYOF ET AL., 2007).
Pharmacological studies revealed that acute and chronic nicotine administration alters opi-
oid peptide levels and expression. A single injection of nicotine led to a dose-dependent in-
crease in striatal preprodynorphin mRNA and dynorphin levels (ISOLA ET AL., 2009). Acute
treatment also induced enkephalin release and increased the transcription of preproenkephalin
mRNA (LIVETT ET AL., 1981; EIDEN ET AL., 1984; MACARTHUR ET AL., 1992; HÖLLT
AND HORN, 1992; HOUDI ET AL., 1991; KIGUCHI ET AL., 2008). In contrast, POMCmRNA
and ß-endorphin plasma levels remained unchanged after acute nicotine administration (OLIVE
ET AL., 2003; WEWERS ET AL., 1994). These data indicate that acute nicotine treatment does
not influence ß-endorphin, but that it modulates enkephalin and dynorphin transcription and
release.
So far, µ-opioid receptor, enkephalin, dynorphin and ß-endorphin knockout mice have been
studied in nicotine conditioned place-preference to assess the rewarding properties of nico-
tine. No change was observed in Pdyn−/− animals. However, these animals acquired nicotine
self-administration with lower doses of nicotine compared to wild type mice, indicating that
the reinforcing effects of nicotine are higher in the absence of dynorphin (GALEOTE ET AL.,
2008). These findings underline the role of dynrophin in mediating dysphoria. The contribu-
tion of enkephalin and ß-endorphin acting on µ-receptors to reward was also approved. Nicotine
was not rewarding in µ-opioid receptor, enkephalin and ß-endorphin knockout mice, as none
of these mice exhibited a place-preference for nicotine (BERRENDERO ET AL., 2002, 2005;
TRIGO ET AL., 2009). The contribution of enkephalin was further evaluated by microdialysis
studies showing an attenuation of dopamine release in the NAc after nicotine injection. Hence,
enkephalins seem to be essential for the activation of mesolimbic reward circuits by nicotine,
presumably by acting on µ-receptors (BERRENDERO ET AL., 2005; DREWS AND ZIMMER,
2009).
To elucidate how enkephalin contributes to nicotine reward and reinforcement in detail, a
closer analysis in specific brain regions is needed. In general, mutant mouse strains lacking
genes of the endogenous opioid system are a useful tool to extend the research on this system.
Nevertheless, in these mice the gene product is absent in all tissues and at all developmental
stages. These mouse models are, therefore, inappropriate to elucidate the gene function in
specific brain regions, cell types or during specific stages of a disease process. Conditional
knockout mouse models (see Box 2), allowing the cell- or tissue-specific deletion of genes,
would help to gain further insights.
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Box 2: Generation of conditional knockout mice using the cre/lox technology:
LoxP sites are short phage-derived sequences that can be introduced into the mouse genome.
The enzyme cre recombinase identifies these sequences and mediates recombination between
two loxP sites. If the two loxP sites have the same orientation, the floxed region will be excised
by cre recombinase-mediated recombination. The tissue-specific or temporary expression of cre
recombinase therefore allows the specific knockout of floxed genes. (KUMAR ET AL., 2009)
1.3 The opioid system and alcohol addiction
In contrast to nicotine, ethanol acts on a variety of neurotransmitter receptors. Alcohol can
inhibit N-methyl-D-aspartic acid (NMDA) receptors in a dose-dependent manner, enhance
the function of GABAA and glycine receptors and potentiate 5-hydroxytryptamine-3 (5-HT,
serotonin) and nACh receptor function (VENGELIENE ET AL., 2008; WANG ET AL., 1994).
Ethanol exposure can influence endogenous opioid peptide expression and alter opioid peptide
release in distinct brain regions associated with reward and reinforcement (GIANOULAKIS,
2004; KOOB ET AL., 1998; SPANAGEL ET AL., 1992). These changes largely depend on
experimental procedures and the brain regions studied. For example, acute ethanol treatment
increased PENK and POMC expression in limbic brain regions like the NAc and the hypotha-
lamus (GIANOULAKIS, 1990; LI ET AL., 1998; RASMUSSEN ET AL., 1998). ß-endorphin
release in the hypothalamus correlated with the ethanol concentration (WAELE ET AL., 1992;
GIANOULAKIS, 1990). Results on enkephalin release were contradictory, some studies found
increased levels after acute ethanol administration, while others did not (SCHULZ ET AL.,
1980; SEIZINGER ET AL., 1983). Dynorphin levels and PDYN mRNA were changed in a
region- and time dependent manner in ethanol-treated rats (GULYA ET AL., 1993; NYLANDER
ET AL., 1994).
The observed expression changes suggest that ethanol exposure influences the activity of
the endogenous opioid system. The endogenous opioid system might, therefore, mediate effects
of ethanol (GIANOULAKIS, 2004; CRABBE ET AL., 2006; KIEFFER AND GAVERIAUX-RUFF,
2002). For example, administration of the nonspecific opioid receptor antagonists naloxone
and naltrexone in rodents led to a dose-dependent decrease in ethanol consumption (ALT-
SHULER ET AL., 1980; FROEHLICH ET AL., 1990; GIANOULAKIS, 2001; MYERS ET AL.,
1986; WEISS ET AL., 1990). Consistently, Nalmefene preferentially antagonizing µ-opioid
receptor signaling suppressed ethanol self-administration in an operant model. This implicates
that µ-opioid receptors play an important role in alcohol reward (JUNE, 2002). Studies on the
δ-opioid receptor suggested a modulatory function as its inhibition attenuated ethanol intake
(CICCOCIOPPO ET AL., 2002; HYYTIA AND KIIANMAA, 2001; KRISHNAN-SARIN ET AL.,
1995A,B). Pharmacological evaluation of κ-opioid receptor signaling led to inconsistent re-
sults. Agonist treatment reduced ethanol preference in rats (SANDI ET AL., 1988; LINDHOLM
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ET AL., 2001). In contrast, the antagonist nor-binaltrophimine (nor-BNI) selectively attenu-
ated ethanol self-administration in alcohol-dependent rats (WALKER AND KOOB, 2008). All
these findings demonstrate a general involvement of the opioid system in ethanol reward and
addiction.
The analysis of µ-opioid receptor knockout mice in ethanol-related behaviors specified the im-
portance of this receptor in mediating the rewarding properties of ethanol. The knockout mice
showed a decreased ethanol consumption or did not self-administer ethanol at all (ROBERTS
ET AL., 2000; HALL ET AL., 2001). In contrast, δ-opioid receptor knockout mice exhib-
ited an increased ethanol preference (ROBERTS ET AL., 2001). This consumption was able
to reverse the previously observed anxiogenic phenotype of these mice (ROBERTS ET AL.,
2001; KIEFFER AND GAVERIAUX-RUFF, 2002). For κ-opioid receptors, a lower ethanol
preference was reported (KOVACS ET AL., 2005). The deletion of preproenkephalin had no
influence on voluntary ethanol consumption patterns or ethanol reward (KOENIG AND OLIVE,
2002; HAYWARD ET AL., 2004; RACZ ET AL., 2008). Opposing results were reported for
ß-endorphin knockout mice. A recent study revealed a decrease in ethanol consumption and
preference, perfectly matching the phenotype of µ-opioid receptor knockout animals (RACZ
ET AL., 2008). Other groups observed comparable or increased ethanol consumption (GRA-
HAME ET AL., 2000; GRISEL ET AL., 1999; HAYWARD ET AL., 2004). It was suggested that
different ambient stress levels led to these divergent results (RACZ ET AL., 2008). It is well
known that stress affects ethanol consumption in mice, and ß-endorphin knockout and wild type
mice differed significantly in their stress-induced ethanol consumption (RACZ ET AL., 2003,
2008). Female preprodynorphin knockout mice exhibited a significantly lower preference in
a two-bottle choice paradigm, which is in line with the phenotype of κ-opioid receptor knock-
out mice (BLEDNOV ET AL., 2006). Since for both strains a reduced saccharine preference
was reported, a more global effect on taste preference was suggested (KOVACS ET AL., 2005;
BLEDNOV ET AL., 2006).
Results obtained in knockout mice provided further insights. δ-opioid receptors seem to
influence alcohol intake via modulation of anxiety-related behaviors. The role for dynorphin
acting on κ-opioid receptors might be due to a decreased orosensory reward of alcohol. The
rewarding properties of ethanol are mostly mediated by ß-endorphin acting on µ-opioid recep-
tors.
The contribution of genetic risk factors to addiction disorders, including alcoholism, is well
established (REICH ET AL., 1999; CRABBE, 2002). The multiple genes contributing to the
aetiology of alcoholism can be accessed by different approaches. One procedure is the anal-
ysis of genetic differences between groups of alcoholic patients and healthy controls. Data
obtained in animals studies and information about biological pathways are merged to select
possible candidate genes. In case of the endogenous opioid system, the knowledge gained in
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animal experiments was already transferred to addiction treatment in humans. The non-specific
opioid receptor antagonists naltrexone is already administered for the pharmacotherapy of al-
cohol addiction (KREEK ET AL., 2002; DREWS AND ZIMMER, 2009). Initial case-control
studies of genetic variants mainly focused on the µ- and the δ-opioid receptor. In case of the
µ-opioid receptor, the A118G coding variant, leading to an exchange of asparagin to aspartate
at position 40, was of particular interest in association studies. Although some groups found
higher frequencies for hetero- or homozygous A allele-carriers among alcoholics, the results
remained inconclusive, as others reported negative findings (ROMMELSPACHER ET AL., 2001;
TOWN ET AL., 1999; BERGEN ET AL., 1997; FRANKE ET AL., 2001; GELERNTER ET AL.,
1999). A meta-analysis of this variant did not reveal evidence of an association with alco-
holism (ARIAS ET AL., 2006). However, there were reports connecting the Asp40 form of
the µ-opioid receptor with higher therapheutic effects of naltrexone and naloxone. This might
be due to differences in antagonist-induced disinhibition of the hypothalamic-pituitary-adrenal
(HPA) axis (KIM ET AL., 2009; CHONG ET AL., 2006; WAND ET AL., 2002). For other
µ-opioid receptor coding variants association results were as well contradictory (XUEI ET AL.,
2007). Concerning the δ-opioid receptor, two coding single nucleotide polymorphisms (SNPs)
were studied. Neither the G80T nor the T921C variant showed association with alcoholism
in alcohol-dependent Taiwanese Hans or Caucasians (LOH ET AL., 2004; FRANKE ET AL.,
1999). Loh et al. also evaluated three SNPs (G36T, C459T, A843G) in theOPRK1 gene encod-
ing the κ-opioid receptor and found no association with alcoholism in Taiwanese Han subjects
(LOH ET AL., 2004). Variants in endogenous opioid peptide genes were only analyzed by two
groups. Geijer et al. did not find an association with a GC/AT base pair exchange located 301bp
upstream of PDYN (GEIJER ET AL., 1997). In the study of Chan et al., a CA repeat in the 5’
flanking region of PENK was not associated with alcohol dependence in populations of Asian,
African-American and Caucasian origin (CHAN ET AL., 1994). To analyze a putative role of
variants in opioid peptide genes a systematic evaluation of these gene loci is needed.
1.4 Aim of this work
Since the discovery of opioid receptors and the first pharmacological studies using morphine
derivates, a tremendous amount of information has accumulated, indicating that the endogenous
opioid system plays a central role in mediating addiction-related behaviors. Depending on
the addictive drug, enkephalin and ß-endorphin vary in their contribution to reward. What
is the specific contribution of these peptides? To gain further insights into different effects
of opioid peptides in distinct brain regions, new tools are demanded. One aim of this work
was therefore the generation of a new mouse model that enables the cell- or tissue-specific
knockout of enkephalin. This will permit to further analyze the contribution of enkephalin for
example to nicotine reward . Stereotactic surgery methods to assess relevant brain regions will
be established for the subsequent analysis of this mouse model.
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Data obtained in animal studies clearly demonstrate that the opioid system is involved in ethanol
reward and addiction. Do variations in opioid peptide or receptor genes contribute to ethanol
addiction in humans? Therefore the second aim of this work was to systematically analyze
the contribution of variants in opioid peptide genes to human alcohol dependence. So far,
variants in opioid peptide coding genes were not systematically studied in human case control
samples. Findings on frequency differences between a group of cases and controls might allow
conclusions if SNPs in opioid peptide genes are responsible for inter-individual differences in
the susceptibility for alcohol addiction.
Chapter 2
Material
If not indicated differently, all applied chemicals are products from Invitrogen, Applichem,
Sigma, Merck, Roche and Roth. In the appendix, contact information of the suppliers are given.
The oligonucleotides were synthesized and delivered by Metabion. Information about primer
sequences are provided in the appendix. TaqMan® gene expression or genotyping assays were
purchased at Applied Biosystems. Chemicals specific for the mass spectrometry-based SNP
genotyping were ordered at Sequenom, Inc. For sequencing, DNA was sent to Macrogen Inc.
in Korea. An overview about the used databases is also given in the appendix.
2.1 Enzymes and antibodies
All restriction endonucleases were purchased from New England Biolabs (NEB). Reverse tran-
scriptase was purchased from Qiagen. DNA polymerases were obtained from both companies.
Antigen Species Modification Company
Antibodies
GFP rabbit Abcam
Digoxigenin sheep alkaline phosphatase conjugated Roche
rabbit IgG donkey biotinylated Jackson
Antisera
Met-enkephalin rabbit Bachem
Leu-enkephalin rabbit Bachem
rabbit IgG donkey Bachem
11
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2.2 Kits
Dig RNA Labeling Kit Roche
PCR Dig labeling mix Roche
peqGOLD Gel Extraction Kit Peqlab
peqGOLD Plasmid Miniprep Kit I Peqlab
PureLinkTM HiPure Midi Plasmid Extraction Kit Invitrogen
QIAquick Nucleotide Removal Kit Qiagen
Peptide Radioimmunoassay Kits Bachem
TSMTMFluorescin System PerkinElmer
Avidin-Biotin Blocking Kit VectorLaboratories
VECTASHIELD Mounting Medium with DAPI VectorLaboratories
2.3 Bacteria, cells and plasmids
TOP10: An E.coli strain obtained from Invitrogen used for the transformation of recombi-
nant plasmids (F-, mcrA, ∆(mrr-hsdRMS-mcrBC), Φ80lacZ∆M15, ∆lacX74, recA1,
araD139, ∆(araleu)7697, galU, galK, rpsL, (StrR), endA1 and nupG).
MPI2 cells: An embryonic stem cell line generated from 129/Sv mice. These cells were
established at the Max Planck Institute Göttingen in the laboratories of Prof. P. Gruss
(VOSS ET AL., 1998).
pPNT-M2-Enk: Targeting vector for the mutation of the murine preproenkepahlin gene lo-
cus. This vector was generated by Monika König in the laboratories of Prof. A. Zimmer
in Bethesda, Maryland (AmpR, NeoR).
Penk ribo: pBluscriptSK vector containing a part of the murine preproenkephalin exon 3.
This vector was provided by Prof. B. Kieffer and used as template for the generation of
the in situ probe (AmpR).
AAV2-Cre: Recombinant adeno-associated virus serotype 2 expressing cre recombinase
fused to GFP under the control of the CAG promotor. This vector was used for stereotac-
tic injection and provided by Prof. B. Kieffer (concentration: 8.9 x 107 vg/µl).
AAV2-GFP: Recombinant adeno-associated virus serotype 2 expressing eGFP under the
control of the CAG promotor. This vector was used for stereotactic injection and pro-
vided by Prof. B. Kieffer (concentration: 4 x 107 vg/µl).
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2.4 Solutions
If not indicated differently all solutions were prepared using sterile deionized H2O.
2.4.1 DNA isolation
Lysis buffer
Tris/HCl, pH 8 100 mM
EDTA, pH 8 5 mM
NaCl 200 mM
SDS 2 % (w/v)
TE buffer
Tris 10 mM
EDTA, pH 8 1 mM
adjusted to pH 7.4
2.4.2 Agarose gel electrophoresis
6x loading
Tris/HCl, pH 7 10 mM
EDTA, pH 8 50 mM
Bromphenol blue 0.03 % (w/v)
Xylene cyanol FF 0.03 % (w/v)
Orange G 0.4 % (w/v)
Ficoll 15 % (w/v)
TAE buffer
Tris-Acetat 40 mM
EDTA, pH 8 0.5 mM
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2.4.3 Cell culture experiments
ES cell medium
DMEM high glucose
FCS (ES cell aproved) 26 % (v/v)
Nonessential amino acids 1.2 % (v/v)
Sodium pyruvat 0.6 % (v/v)
β-mercaptoethanol 0.2 % (v/v)
LIF 2 ng/ml
Penicillin 3 U/l
Streptomycin 3 U/l
Selection medium
DMEM high glucose
FCS (ES cell aproved) 26 % (v/v)
Nonessential amino acids 1.2 % (v/v)
Penicillin streptomycin mix 0.6 % (v/v)
Sodium pyruvat 0.6 % (v/v)
β-mercaptoethanol 0.2 % (v/v)
LIF 2 ng/ml
G418 170 ng/ml
FIAU 130 nM
Fibroblast medium
DMEM high glucose
FCS 10 % (v/v)
Penicillin streptomycin mix 0.6 % (v/v)
Sodium pyruvat 0.5 % (v/v)
Freezing medium
DMEM
FCS 50 % (v/v)
DMSO 10 % (v/v)
Mitomycin solution
Fibroblast medium
Mitomycin C 10 µg/ml
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2.4.4 Southern blot
Depurination
HCl 250 mM
Denaturation
NaOH 500 mM
NaCl 1.5 M
Neutralisation
Tris/HCl 500 mM
NaCl 1.5 M
20x SSC
NaCl 3 M
Na-citrat dihydrate 300 mM
adjusted to pH 7
Maleic acid buffer
Maleic acid 100 mM
NaCl 150 mM
adjusted to pH 7.5
10x Blocking solution
Maleic acid buffer
Blocking reagent 10 % (w/v)
autoclaved at 121°C, 20 min
Hybridization buffer
20x SSC 25 % (v/v)
SDS 0.2 % (w/v)
10x blocking solution 10 % (v/v)
N-lauroylsarcosine 1 % (w/v)
Washing buffer
Maleic acid buffer
Tween 20 0.3 % (v/v)
Detection buffer
Tris/HCl pH 9.5 100 mM
NaCl 50 mM
MgCl2 25 mM
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2.4.5 In situ hybridization
DEPC-water
DEPC 0.1 % (v/v)
autoclaved at 121°C, 20 min
10x DEPC-PBS
NaCl 1.4 M
PO4 buffer 100 mM
KCl 30 mM
DEPC 0.1 % (v/v)
autoclaved at 121°C, 20 min
PFA/PBS
10x DEPC-PBS 10 % (v/v)
Paraformaldehyde 4 % (w/v)
Triethanolamine solution
Triethanolamine, pH 8 100 mM
Acetic anhydrid 0.2 % (v/v)
20x SSC
NaCl 3 M
Na-citrat dihydrate 300 mM
adjusted to pH 7
DEPC 0.1 % (v/v)
autoclaved at 121°C, 20 min
10x Salts
NaCl 3 M
Tris-HCL, pH 6.8 200 mM
EDTA 50 mM
NaH2PO4 54 mM
Na2HPO4 46 mM
50x Denhardt’s solution
Ficoll 1 % (w/v)
Polyvinylpyrrolidone 1 % (w/v)
Bovine serum albumine 1 % (w/v)
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Hybridization mix
Formamide 50 % (v/v)
Dextran sulfate 10 % (w/v)
10x salts 10 % (v/v)
50x Denhardt’s solution 2 % (v/v)
tRNA 500 µg/ml
Washing buffer
Formamide 50 % (v/v)
Tween20 0.1 % (v/v)
20x SSC 5 % (v/v)
Maleic acid buffer
Maleic acid 100 mM
NaCl 150 mM
adjusted to pH 7.5
autoclaved at 121°C, 20 min
MABT
Maleic acid buffer
Tween20 0.1 % (v/v)
TBST
NaCl 150 mM
Tris/HCl 100 mM
adjusted to pH 7.5
autoclaved at 121°C, 20 min
Tween20 0.1 %
NTMT
NaCl 100 mM
Tris/HCl, pH 9.5 100 mM
MgCl2 50 mM
Tween20 0.1 % (v/v)
Staining solution
NTMT
NBT (Roche) 0.45 % (v/v)
BCIP (Roche) 0.35 % (v/v)
Levamisole 100 µM
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2.4.6 LacZ staining
Basic solution
PBS
MgCl2 2 mM
EGTA, pH 8 5 mM
Glutaraldehyde solution
Basic solution
Glutaraldehyde 0.2 % (v/v)
Staining solution
Basic solution
Sodium doxycholat 0.1 % (w/v)
Nonidet P40 0.02 % (v/v)
K3[Fe(CN6)] 10 mM
K4[Fe(CN6)] 10 mM
X-gal 0.5 mg/ml
Washing buffer
Basic solution
Sodium doxycholat 0.1 % (w/v)
Nonidet P40 0.02 % (v/v)
2.4.7 Immunofluorescence staining
Peroxidase-neutralization reagent
PBS
H2O2 1 % (v/v)
NaN3 0.1 % (v/v)
TNB
Tris/HCl, pH 7.5 100 mM
NaCl 150 mM
Blocking reagent (TSA-Kit) 0.5 % (w/v)
stored at -20°C
Fc-Block
Anti-mouse CD 16/32 purified 1 % (v/v)
Normal rat serum 1 % (v/v)
Normal mouse serum 1 % (v/v)
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2.4.8 Anesthesia
Ketamine/Xylazine
NaCl 0.9 % (w/v)
Ketamine 0.5 % (w/v)
Xylazine 0.2 % (w/v)
Chapter 3
Methods
The methods used in this work are divided into six parts. In the first section, the methods rele-
vant for the cultivation of mouse embryonic stem cells are stated. The second section deals with
the molecular biological experiments conducted in the context of the newly developed mouse
strain, whereas the methods used for the human case-control studies are stated in a separate
section. The methods applied in the context of protein extraction, quantification and activity
measurement are itemized in the fourth section, followed by the description of all animal ex-
periments in section five. The chapter ends with an introduction of the statistical methods used.
3.1 Cell culture methods
In this section all methods relevant for the cultivation of mouse embryonic stem cells (ES cells)
are stated. The experiments were conducted in the laboratories of the Institute of Molecular
Psychiatry at the University Medical Center in Bonn.
3.1.1 Cultivation of cells
All cells were cultivated at 37°C in an incubator with 5% CO2 and humid atmosphere on mono-
layers of mitotically inactivated mouse embryonic fibroblasts (MEF) as feeder cells. When ES
cells reached 70% confluency, or, at the latest, every second day, cells were splitted at a ratio of
1:3 to 1:7. The ES cells were incubated in 25% of the culture volume trypsin/EDTA. The diges-
tion was stopped by adding the same amount of ES cell medium. Subsequently, the cells were
spun down (2 min, 1200 rpm). After gentle resuspension in medium, the cells were dispensed
on fresh feeder plates.
21
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3.1.2 Generation of embryonic mouse fibroblasts
Mouse embryonic fibroblasts were derived from E13.5 embryos. Matings of wild type mice and
mice carrying a neomycin resistance gene were used. Mouse embryos from one or two pregnant
mice were dissected. Subsequently the embryo’s limbs were removed, internal organs were
scooped out and discarded. The small pieces of the minced embryo were incubated in 30 ml
Trypsin/EDTA for 15–20 minutes (37°C, 5% CO2, 95% humidity). During this period the tube
was shaken gently every third minute. After centrifugation (2 min at 1200 rpm) the pellet was
resuspended in 25 ml fibroblast medium and transferred to a cell culture dish. After 3–4 days
cells were grown to confluency and were subcultivated. Following an additional incubation time
of 2–3 days, cells were prepared for long-term storage at – 80°C.
3.1.3 Storage and re-cultivation of cells
Cells were spun down, dispersed in freezing medium and stored in cryotubes at – 80°C. For
long-term storage, the tubes were transferred to liquid nitrogen after 2–3 days.
For re-cultivation cells were thawed quickly, diluted in medium, spun down, resuspended
in fresh medium and transferred to cell culture dishes.
3.1.4 Electroporation and isolation of recombinant ES cell clones
For electroporation, a culture of early-passage ES cells, grown on 15 cm cell culture dishes,
was used. Per electroporation 2 x 107 cells were utilized. The medium was changed 1–2 hours
before harvesting the cells. Subsequent to counting the cells in a hemacytometer they were
spun down (2 min, 1200 rpm), washed and resuspended in HBSS. The suspension and 20 µl
of prepared plasmid DNA (1 µg/µl) were transferred to an electroporation cuvette and a pulse
of 250 V and 500 µF was applied. The cuvette was rinsed and cells were directly passed to a
feeder plate. Selection was initiated 24 hours later by adding selection medium containing the
antibiotic (G418) and FIAU. The medium was changed daily over a period of 7–9 days. Then,
single colonies were transferred into a 24 well plate, each containing one drop of trypsin/EDTA.
After dispersing the ES cells in 1 ml of ES cell medium, feeder cells were added and cultures
were allowed to grow for 24 hours. The medium was renewed and cells were cultivated for
3–4 days. For storage, clones were harvested by trypsination and resuspended in 1 ml freezing
medium, of which an aliquot of 750 µl was frozen. The remaining cells were cultivated further
to obtain DNA for Southern blot analysis.
3.2 Molecular biology methods
The biomolecular experiments described in this section were also conducted in the laboratories
of the Institute of Molecular Psychiatry. Standard methods, as agarose gel electrophoresis,
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ethidium bromid staining or transformation and cultivation of E.coli were performed according
to Molecular Cloning by Sambrook and Russel (SAMBROOK AND RUSSELL, 2001).
3.2.1 DNA preparation
Plasmid-DNA was amplified using E.coli cultures. The DNA was isolated using commercial
kits. Depending on the required amount of DNA Mini-, Midi- or Maxi-preparation kits were
used.
The material was incubated in lysis buffer at 56°C overnight with agitation (550 rpm) to
isolate genomic DNA from cell lines or mouse tail biopsies. After spinning down non-soluble
material, DNA was precipitated by adding isopropanol (1:1) to the supernatant. Subsequent to
washing the pellet with 70 % ethanol the DNA was dried and eluted in TE-buffer.
3.2.2 Determination of nucleic acid concentration
The concentration of nucleic acids was determined using the spectrophotometer NanoDrop ND-
1000. To calculate the nucleid acid concentrations (ng/µl), the following extinction coefficients
were used:
double-stranded DNA: 50 1cm∗M
single-stranded RNA: 40 1cm∗M
3.2.3 Digestion of DNA
Sequence-dependent hydrolysation of DNA was performed using restriction endonucleases and
the appropriate buffers. Preparative digestions were performed overnight using up to 10 µg
DNA, whereas digestion for analytical purposes lasted one hour using up to 1 µg DNA.
3.2.4 Purification of DNA fragments
DNA fragments were purified using either commercial kits for nucleotide removal or phenol-
chloroform extraction. For phenol-chloroform extraction the sample was adjusted to 700 µl and
the same amount of phenol/chloroform/isoamylalcohol (25:24:1) was added. After a thorough
mixing and centrifugation, the aqueous phase was transferred to a fresh tube and the procedure
was repeated. The supernatant was mixed with chloroform, followed once again by phase
separation. Finally the DNA was precipitated by adding 3 M sodiumacetat and ethanol. After
washing with 70% ethanol, the pellet was dried and resolved in the appropriate amount of TE-
buffer.
3.2.5 Reverse transcription
mRNA was transcribed into cDNA for expression analysis. For the generation of cDNA the
Omniscript Reverse Transcriptase from Qiagen was used together with the RNase inhibitor
3.2. MOLECULAR BIOLOGY METHODS 24
RNase OUT and oligodT primer (Invitrogen). In each individual reaction a maximum of 2 µg
of RNA was transcribed.
3.2.6 Polymerase-chain reaction
Specific amplification of DNA fragments was achieved using polymerase-chain reaction (PCR).
The reaction and temperature profiles were specifically adjusted according to the thermody-
namic properties of the oligonucleotide primer and the lengths of the amplified PCR products.
PCR setup Southern probe
The Southern blot probe was marked using Digoxigenin labeled nucleotides.
PCR-setup (50 µl):
26.75 µl sterile water
5 µl 10x PCR-buffer HotStarTaq (Qiagen)
10 µl 5x Q-solution HotStarTaq (Qiagen)
5 µl Dig-labelling dNTP Mix
1 µl 5-Primer (10 µM)
1 µl 3-Primer (10 µM)
1 µl Wt ES cell DNA (≈ 400 ng/µl)
0.25 µl HotStarTaq polymerase (5 U/µl)
Cycling parameters:
I Intitial denaturation 96°C 15 min
II Denaturation 94°C 15 sec
35 cycles III Annealing 55.5°C 45 sec
IV Elongation 72°C 60 sec
V Final elongation 72°C 10 min
VI Cooling 4°C ∞
Expression analysis using quantitative realtime PCR
SYBR green or TaqMan® expression assays were used to quantify the amount of a specific
mRNA. The dye SYBR Green intercalates during cDNA amplification, whereupon a fluores-
cence signal is emitted. TaqMan® assays are based on fluorogenic probes. The fluorescence
signal is transmitted after binding of this probe to a specific cDNA sequence during amplifica-
tion. TaqMan® assays were applied to differentiate between splice variants of the Penk1 gene.
For both methods the intensity of the fluorescence signal was monitored using a 7900HT Fast
Real-Time PCR System and intensity differences were quantified after normalization to a house
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keeping gene (beta-actin) (LIVAK AND SCHMITTGEN, 2001). The TaqMan® assays were con-
ducted as described by the manufacturer. For SYBR green-dependent detection the following
set up was used:
PCR setup (20 µl):
6.5 µl sterile water
10 µl 2x SYBR Green JumpStart Taq ReadyMix
1 µl 5-Primer (10 µM)
1 µl 3-Primer (10 µM)
1.5 µl cDNA
Cycling parameters:
I Initial denaturation 94°C 2 min
II Denaturation 94°C 15 sec
40 cycles
III Annealing 56°C 30 sec
IV Elongation 72°C 30 sec
V Fluorescence detection
VI Melting curve measurement
3.2.7 In vitro transcription
In vitro transcription was conducted to obtain Dig-labeled RNA probes for in situ hybridization.
Briefly, 1 µg linearized purified template plasmid DNA was incubated for 2 hours at 37°C with
SP6, T7 or T3 RNA polymerase (Roche). To remove template DNA 2 µl of DNaseI was added
followed by a 15 min incubation at 37°C. The reaction was stopped by adding 2 µl of 0.2 M
EDTA (pH 8). The RNA was then precipitated by adding 72 µl of ammonium acetate together
with 470 µl of absolute ethanol, incubated at – 80°C for 20 min and spun down at 13 000 rpm
(20 min). The air-dried pellet was resolved in 22 µl DEPC-water and stored at – 80°C until
further use. The quality of the probe was controlled by agarose gel electrophoresis.
Labeling reaction:
2 µl 10x NTP labeling mixture (Roche)
2 µl 10x transcription buffer (Roche)
1 µl RNase inhibitor (Roche)
2 µl RNA polymerase (Roche)
13 µl Template DNA and DEPC-water
3.2.8 Southern blot
Screening of mouse embryonic stem cell clones for homologous recombination and analysis of
mouse tail biopsies was done by Southern blot. Here, specific DNA fragments crosslinked to a
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nylon membrane were detected using digoxigenin-labeled probes.
Digested DNA was separated in an agarose gel and the gel was prepared for blotting. The
DNA was depurinated for 10 min followed by denaturation and neutralization (30 min each).
Blotting was performed in 10x SSC for 1.5 hours at 5 bar. Via UV-crosslinking, the DNA was
immobilized on the membrane before hybridization with denatured probes at 65°C overnight.
Unspecific binding was avoided by prehybridisation with salmon sperm DNA.
The next day, the membrane was incubated twice for 10 min in 2x SSC/0.1% SDS at room
temperature, followed by incubation in 0.2x SSC/0.1% SDS at 65°C (3 x 10 min). Subse-
quently, the membrane was equilibrated in maleic acid buffer. Prior to adding anti-digoxigenin
antibody (1:20 000) for 40 min, an incubation in blocking solution (one hour) was conducted
to prevent unspecific binding. Afterwards three washing steps (10 min in washing buffer) were
performed. After equilibration for 5 min the detection was done with CDP-Star (Roche) diluted
1:100 in detection buffer. The results were monitored by exposure to a hyperfilm (Amersham
Pharmacia) for approximately 35 min.
3.2.9 In situ hybridization
For qualitative expression analysis in situ hybridization was conducted. Cryosections (see sub-
section 3.5.2) of 10 µm were dried for 30 min prior to 10 min of fixation in PFA/PBS. After
washing in PBS (2x 10 min), the slides were acetylated in a triethanolamin solution. The
subsequent washing steps were performed in 2x SSC (10 min), followed by dehydration via
incubation in ascending ethanol concentrations (60–100%). To remove lipids, immersion in
chloroform was used. After incubation in descending ethanol concentration (100–80%), the
slides were dried at room temperature for 30 min. For denaturation, the hybridization mix con-
taining the in situ probe (2ng/µl) was preincubated at 70°C for 10 min. Next the sections were
hybridized in a humid chamber at 65°C overnight, washed twice for 30 min in washing buffer
and incubated in MABT (2x 30 min, room temperature). Blocking of unspecific binding was
done for 1 hour in blocking solution followed by incubation with anti-digoxgenin antibody in
a humind chamber at 4°C for either 2 hours or over night. To remove excess antibody the
sections were washed 5 times for 20 min in TBST. The staining reaction was prepared via incu-
bation in NTMT (2x 10 min). Freshly prepared staining solution was spread on the slides before
overnight incubation in a humid chamber. The staining reaction was stopped by washing with
TE-buffer. After drying the slides were embedded and covered for microscopic examination.
3.2.10 RNA isolation
Following tissue sample preparation (see subsection 3.5.1) RNA was isolated through homog-
enization in TRIzol® reagent. To gain high amounts of RNA, it is important that the tissue
volume should not exceed 10% of the overall volume. The homogenate was pressed five
times through a 21G needle using a syringe. After 5 min incubation the probe was spun down
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(12 000x g 10 min, 4°C) to sediment nonsoluble ingredients. After adding BCP (10% of the
inital amount TRIzol®) the probe was mixed for 30 s via vortexing. After an incubation time of
three minutes, phase separation was obtained by centrifugation (12 000x g, 15 min, 4°C). The
aqueous phase containing RNA was transferred into a fresh cap and the RNA was precipitated
by adding isopropanol (50% of the initial TRIzol® volume) and spun down at 12 000x g, 4°C
for 15 min. After washing with 70% ethanol, the pellet was dried and dissolved in DEPC-H2O.
3.3 SNP genotyping
Frequency differences of polymorphic markers between two groups of human subjects were
assessed by SNP genotyping. The genotyping using the MassARRAY platform Sequenom
were performed in cooperation with Prof. Dr. M. Nöthen and Dr. A. Karpushova from the In-
stitute of Human Genetics, University of Bonn. All other experiments were performed in
the laboratories of the Institute of Molecular Psychiatry. The samples were provided by
Prof. W. Maier (Department of Psychiatry, Bonn), Prof. M. Nöthen (Institute of Human Ge-
netics, Bonn), Prof. L. Terenius (Karolinska Institute, Sweden) and Prof. M. Reuter (Institute of
Psychology, Bonn).
3.3.1 Human subjects
An overview of all genotyped cohorts is given in figure 3.1. DNA of 154 patients with a def-
inite current DSM-IV diagnosis of alcohol dependence (90 men, 64 women) and 206 control
subjects consisting of German blood donors (154 males, 52 females) was analyzed for an initial
exploratory genotyping. For an extensive genotyping the cases group was extended and the
control sample was changed. DNA of 247 patients with a definite current DSM-IV diagnosis
of alcohol dependence (180 men, mean age = 42.0± 9.0; 67 women, mean age = 44.3± 8.5)
was available and 247 population-based control subjects were selected with regard to gender
and age (180 men, mean age = 41.7 ± 8.9; 67 women, mean age = 44.2 ± 8.4). Further, the
sample size of the female subgroup was increased for two markers (rs934778 and rs3769671) to
83 (67+16) female patients (mean age = 44.4± 8.6) and 140 (67+73) female control subjects
(mean age = 45.8± 9.6).
Substance abuse and dependence (including alcohol and illicit drugs) as well as psychi-
atric disorders were assessed with the whole Structured Clinical Interview for DSM-IV Axis I
Disorders (SCID). An experienced psychiatrist was responsible for the DSM-IV diagnosis of al-
coholism on the basis of the SCID-interview and all available clinical information and records.
Subjects that additionally met DSM-IV criteria for dependence on an illicit drug, or had suf-
fered recently (within 1 year) from any major psychiatric disorder, were excluded. History of
psychiatric disorders such as a depressive episode did not lead to exclusion. Patients were re-
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Fig. 3.1: Illustration of the genotyped samples. First an exploratory genotyping was performed
using a small number of cases and controls. For an extensive genotyping the number of cases was
increased and a population-based control sample was selected (German sample). For two markers
the number of female cases and controls was further increased (rs934778 and rs3769671). A cohort
of Scandinavian ancestry served as a replication cohort (Swedish sample).
cruited at the Department of Psychiatry (University of Bonn) or by collaborating psychiatric
hospitals in Düsseldorf, Mainz, and Essen.
The population-based control sample of Caucasians of German origin was collected with
the support of the local Census Bureau of the City of Bonn. The sample was established within
the framework of the German National Genome Research Network I (NGFN I) of the Federal
Ministry of Education and Research between 2000 and 2003 and serves as an epidemiological
control sample for complex genetic studies within the NGFN.
To verify findings, a group of 120 healthy women (mean age = 29.5 ± 10.1) and a group
of 72 female alcoholic subjects (mean age = 47.3 ± 10.6) were additionally genotyped for
two markers (rs934778 and rs3769671). The female patients were recruited in the Clinic Es-
chenburg, a hospital specialized in the treatment of alcohol abuse and alcoholism. They met
the ICD-10 criteria for alcohol dependence (F10.25) of the World Health Organization (WHO)
and were committed to the rehabilitation clinic after alcohol detoxification. They participated
in the study directly after admission to the Clinic Eschenburg. The individuals of this group
had no clinical diagnosis of dependence on illicit drugs. All patients and control subjects were
Caucasians of German origin.
Alcoholic patients (240 men, mean age = 47.25 ± 10.65; 114 women, mean age =
46.09± 10.39) and control subjects (202 men, 113 women) of Scandinavian ancestry served as
a replication cohort. The affected individuals were collected within the Swedish Alcoholism in
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Siblings Study. Alcoholism was defined according to DSM-IV criteria after a structural psychi-
atric interview with the Schedules for Clinical Assessment in Neuropsychiatry. The comorbid-
ity with any other psychiatric disorder was below 1%. The group of healthy control individuals
consisted of Swedish blood donors (202 men, 113 women). For this group no information
concerning the age of the control subjects was available.
3.3.2 SNP selection and genotyping
To select appropriate markers representing genes of interest, data of linkage disequilibrium (LD)
is taken into account. On the website of the international HapMap project information on LD in
reference populations can be retrieved. Using the program haploview, haplotype blocks (highly
linked regions) and tagging markers, which cover most of the genomic variance in the region of
interest, can be calculated. In the initial phase of the present dissertation project this information
was not available for genes encoding endogenous opioid peptides. Therefore markers evenly
distributed across the gene loci of interest were chosen. A second criteria for SNP selection was
the availability of appropriate genotyping assays.
For the extensive genotyping HapMap Phase II data were available and the LD information
was taken into account. According to HapMap project data for Caucasians, the predicted tag-
ging SNPs for PENK and PDYN were analyzed. In contrast, markers of the human POMC gene
locus showed weak LD. Therefore SNPs were selected randomly with an average spacing of 3
kb.
The initial and the additional genotyping (for rs934778 and rs3769671) were realized using
Assays-On-Demand SNP Genotyping products. For the extensive genotyping matrix-assisted
laser desorption/ionization time-of-flight (MALDI-TOF) mass spectrometry-based SNP geno-
typing was performed using the MassARRAY System according to the manufacturer’s speci-
fications. Genotyping was done using Sequenom iPLEX chemistry, which is based on single
base pair extension utilizing modified nucleotides.
3.4 Protein biochemical methods
The different methods used to detect peptides and proteins are described below. All experiments
were conducted in the laboratories of the Institute of Molecular Psychiatry.
3.4.1 Radioimmunoassay
Radioimmunoassay (RIA) protocols for Met-enkephalin and Leu-enkephalin were established
to assess the amount of the main enkephalin peptides in the brain. Therefore, mouse brains
were homogenized in 3 ml of 2 N acetic acid at 4°C and clarified at 15 000x g for 30 min
at 4°C. Initially duplicate aliquots of 10, 50, and 100 µl of the homogenate were dried under
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vacuum in polystyrene tubes, resuspended in 100 µl of RIA buffer, and assayed following the
protocol for the S-2118 Leu-Enkephalin and S-2119 Met-Enkephalin Radioimmunoassay kit.
Later, duplicate aliquots of 100 µl sample were assayed. The standard curve for these kits
ranged from 0.1 to 64 pg.
3.4.2 LacZ staining
The bacterial ß-galactosidase gene (lacZ) is frequently used as a reporter gene. The expression
of transgenic constructs can be monitored by histochemistry with the chromogenic substrate
X-gal. It enables precise cellular localization of gene activity. Tissue sections were prepared
as described in subsection 3.5.2. Slides were fixed in glutaraldehyde solution for 5 min. After-
wards the sections were incubated twice for 10 min in washing buffer, followed by an incubation
in freshly prepared staining solution overnight at 37°C. On the next day the staining reaction
was stopped by rinsing the slides in tap water. Counterstaining was performed using nuclear
fast red. After drying, the slides were embedded and covered for microscopic examination.
3.4.3 Immunofluorescence staining
For visualization of eGFP expression in tissue sections, immunofluorescence staining was
conducted. First the slides were incubated in peroxidase-neutralization reagent (1 hour) and
subsequently washed two times in PBS. Next, unspecific immune complex binding to im-
munoglobulin Fc receptors was prevented by incubation in Fc-Block for 25 minutes followed
by Avidin-block (20 min) and Biotin-block (20 min). For specific antigen detection, anti-GFP
antibody (1:2000 in TNB) was added and the sections were kept at 4°C overnight. The sec-
ondary biotinilated antibody was incubated (1:500 in TNB) for 30 min at room temperature.
Afterwards the secondary antibody was bound by Streptavidin-HRP (1:200 in TNB). For anti-
body detection FITC-tyramide diluted in amplification buffer (1:100) was added and incubated
in the dark (8 min). After each incubation the slides were rinsed two times in PBS. At the
end the sections were mounted using VECTASHIELD mounting medium containing DAPI and
kept at 4°C until microscopic examination.
3.5 Animal experiments
Behavioral experiments were conducted at the animal facility of the University Medical Cen-
ter. The microinjection service of this facility was utilized to obtain chimeric mice. The S1
(Sicherheitsstufe 1, §§4-7 GenTSV) animal facility provided standardized climatic conditions.
For behavioral testing all animals were housed under reversed light-dark conditions (lights on at
7:00 p.m. and lights off at 7:00 a.m.). Animal care and experiments described in this work were
approved by legal authorities (Landesamt für Natur, Umwelt und Verbraucherschutz NRW).
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All procedures were in compliance with national regulations (Tierschutzgesetz v. 18.5.2006
(BGBl. I S. 1206, 1313), g v. 18.12.2007 (BGBl. I S. 3001; 2008, 47)) and institutional
guidelines. Cage allocation conformed the prescribed number of animals. Generally, mice are
housed in groups of up to six animals. Mice were housed individually if this was necessary for
the respective experiment. The animals had free access to food and drinking water.
The nicotine self-administration experiments were conducted by Dr. J.M. Trigo in the labo-
ratory of Prof. R. Maldonado in Barcelona, Spain.
3.5.1 Tissue preparation
Mice were sacrificed via cervical dislocation, the required tissue was removed rapidly and im-
mediately shock-frozen in isopentan bedded on dry ice. If a mouse tissue was utilized for
immunofluorescence staining, mice were anesthetized using a ketamine/xylazine mixture and
perfused using PBS. Subsequent to preparation the tissue was transferred to 4% PFA solution
and fixed for up to 6 hours. Cryprotection was achieved by incubation of the tissue in 20%
sucrose solution. Tissue samples were stored at – 80°C until further use.
3.5.2 Preparation of tissue sections
Prepared tissue samples were put on dry ice, embedded in Tissue Tec and sectioned to a thick-
ness of 10-20 µm using a cryostat (cm 3050 S, Leica) at a temperature of – 24 to – 18°C. The
sections were dried quickly at room temperature and either directly fixed or stored at – 80°C.
3.5.3 Generation of chimeric mice
Chimeric mice were obtained by blastocyst injection. Therefore cells of a targeted ES cell
line were injected into blastocysts harvested from superovulated 4-6 week old C57BL/6J mice
(Charles River). Blastocysts were then retransfered to pseudo-pregnant foster animals. The
quality of chimeric animals was evaluated by coat color and the transmission to their progeny.
Chimeric animals were backcrossed to the C57BL/6J mouse strain.
3.5.4 Deletion of the neomycin gene
Mice carrying the floxed preproenkephalin gene locus were bred to mice expressing cre recom-
binase under the control of an early acting promoter. Two different cre recombinase-expressing
strains were used to delete the neomycin (neo) gene. First Pgk-cre mice, expressing cre recom-
binase under the Pgk1 promoter (LALLEMAND ET AL., 1998), second EIIa-cre mice, express-
ing cre recombinase under EIIa promoter, were mated to Penk1wt/lox animals. The later mouse
strain is known to generate a mosaic pattern of deletion due to incomplete cre recombinase-
mediated recombination (LAKSO ET AL., 1996).
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3.5.5 Anxiety measurement
The zero maze apparatus used for anxiety measurements consisted of an annular white platform
(inner diameter of 46 cm, 5.6 cm width) elevated 40 cm above the ground level (Fig. 3.2). It
was divided into four equal quadrants, whereas non-transparent walls enclosed two opposite
quadrants. Each mouse was placed into the open area of the maze. The animals’ behavior
was videotaped by a camera fixed above the maze and analyzed using a video-tracking system
(VideoMot; TSE Systems). Between subjects the apparatus was cleaned with a 70% ethanol
solution. Distance traveled in the open parts of the maze in relation to the total distance, the
time spent in the open area and the latency to enter the closed area were evaluated as parameters
for anxiety.
Fig. 3.2: Zero maze. The maze is divided into four equal quadrants, whereas non-transparent walls
enclose the two opposite quadrants. At the beginning of the test the mouse is placed into the open
area of the maze.
3.5.6 Stereotactic injection
Stereotactic surgery is a minimally invasive form of surgical intervention. It makes use of a
three-dimensional coordinate system to locate small targets inside the organism and to perform
localized actions such as injection, stimulation and implantation. For orientation within the
mouse brain, the mouse stereotactic brain atlas (PAXINOS AND FRANKLIN, 2001) was used.
Bregma, the craniometric point at the junction of the sagittal and coronal sutures at the top
of the cranium, served as a reference point. Stereotactic injections were performed to target
specific regions of the mouse brain in order to obtain regional deletion of the Penk1 locus.
For this purpose cre recombinase expressing adeno-associated viruses – or GFP expressing
AAVs as a control – were injected into the brain region of interest. The targeting of a specific
region using the virus approach works best if the infusion rate is not higher than 0.05-1 µl/min.
Therefore, a specific setup needed to be established (Fig. 3.3). Anesthesia was induced via
inhalation of isofluran. Subsequently, mice were placed in a stereotactic frame and received a
constant stream of an oxygen/isoflurane mixture to maintain anesthesia. This guaranteed that
mice stayed narcotized for the long-lasting surgery. After midline incision of the scalp, the
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Fig. 3.3: Set up for sterotactic injection. To allow simultaneous bilateral assessment of a brain
region a specific device was added to the stereotactic frame. For virus injection two glass capillaries
with tip resistance of 2–4 MΩ attached to a 50 ml syringe via small flexible tubes were used. During
surgery the scull of the mouse was fixed by two earbars and a nose clamp. To maintain anesthesia
mice received a constant flow stream of oxygen/isoflurane via a mask around the nose clamp.
bregma area was exposed and two small openings were made with a dental drill, at the appro-
priate coordinates for the brain region of interest. To allow simultaneous bilateral assessment
– also to decrease the duration of surgery – a specific device was added to the stereotactic
frame as shown in figure 3.3. To inject the virus two glass capillaries with tip resistance of
2–4 MΩ attached to a 50 ml syringe via small flexible tubes were used. They were inserted
stereotactically through the holes ventral to the dura into the brain region that was targeted.
By pushing the syringe, pressure was built up for a slow injection of the virus. To target the
nucleus accumbens 2 µl virus were injected. Mice quickly recovered from surgery and further
experiments were conducted after two weeks.
3.5.7 Nicotine self-administration
For the analysis of nicotine self-administration a permanent catheter was implanted intra-
venously to allow self application of nicotine via nose-poking in an operant model. Briefly,
mice were narcotized with a ketamine/xylazine mixture and then implanted with indwelling
3.6. STATISTICAL METHODS 34
i.v. silastic catheters as previously described (SORIA ET AL., 2005). The self-administration
experiments were conducted in mouse operant chambers equipped with two holes, one ran-
domly selected as the active sensor and the other as the inactive sensor. Nicotine was infused
via a syringe that was mounted on a microinfusion pump and attached to the mouse intra-
venous catheter. The whole procedure is described in detail by Martin-Garcia and co-workers
(MARTÍN-GARCÍA ET AL., 2009).
3.6 Statistical methods
Data obtained from mouse experiments were analyzed using the methods named in the subsec-
tion general statistics, whereas the statistical methods for the analysis of case-control data is
described in a separate subsection. P-values < 0.05 were considered to be significant.
3.6.1 General statistic
In the case of mouse experiments, differences between genotypes were analyzed using one-way
ANOVA followed by Bonferroni post hoc test. If raw data did not follow a normal distribution,
data were transformed by calculating the log10-values followed by statistical analysis. Data of
the nicotine self-administration experiment were analyzed by repeated measure ANOVA. The
software Graph Pad Prism 4.0 was used for statistics and generation of graphs.
3.6.2 Case control study
Statistical analysis was performed with the program FAMHAP version 17. To calculate unad-
justed p-values for association of single markers the option singleccwas used. Using this option
the program calculates three different p-values for each marker (allelic, global and Armitage
p-value) to detect significant differences in allele frequencies or genotype distributions between
cases and controls. Significant differences of allele frequencies among cases and controls were
calculated via a χ2- based test (allelic p-value). The global p-value for differences in genotype
distributions was computed in the same way. Additionally the Armitage trend test p-value
was calculated to analyze significant differences in genotype distributions. When groups are
ordered the Armitage trend test is typically used in categorical data analysis. In case of the
genotype distribution groups are ordered by the dosage of a specific allele that means they are
classified in non-carriers and in carriers of one or two alleles. By considering this ordered
categories the Armitage test detects the significant difference in genotype distributions between
cases and controls and whether the distributions show a significant trend depending on the
allele dosage (ARMITAGE, 1955). This makes the Armitage trend test more robust against
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stratification effects that might lead to false positive results (ARMITAGE, 1966). For haplotype
analysis, FAMHAP estimates haplotype frequencies with the expectation-maximization (EM)-
algorithm. P-values were computed by a permutational χ2- based test (BECKER AND KNAPP,
2004). Pair-wise LD and haplotype block structure based on the control data was visualized
using the HAPLOVIEW program v.3.32 (BARRETT ET AL., 2005). Block definition was done
according to criteria proposed by Gabriel and co-workers (GABRIEL ET AL., 2002). For single
marker analysis a Bonferroni correction for multiple testing was applied.
Chapter 4
Results
Two different approaches were used to enlighten the role of endogenous opioid peptides in
drug addiction. One approach was the development of a new mouse model with a floxed pre-
proenkephalin locus to elucidate the function of enkephalin in specific brain regions or cell types
in the context of nicotine addiction. The introduction of loxP sites into the genome allows the
subsequent excision of the embedded region via cre recombinase-mediated recombination. The
excision depends on cre recombinase activity which enables the tissue or cell-specific deletion
of the corresponding gene region. The second approach included the analysis of polymorphisms
in human opioid peptide genes. Single nucleotide polymorphisms were studied for frequency
differences between alcoholic patients and corresponding control groups.
4.1 Generation of floxed preproenkephalin mice
In this section all experiments concerning the generation of the floxed preproenkephalin mouse
line are described.
4.1.1 Targeting strategy
The targeting vector pPNT-M2-enk is depicted in figure 4.1. It was derived from the pPNT-
M2 vector by introducing a 5.7 kb fragment containing all three exons of the murine pre-
proenkephalin locus. This 5.7 kb fragment served as 5’ homology. Directly upstream of exon
2, a loxP site was added. As a selectable marker for ES cell culture a neomycin resistance gene
flanked by two loxP sites was inserted downstream of exon 3. A lacZ gene was introduced
to function as a reporter gene after cre recombinase-mediated excision of the coding exons 2
and 3. Therefore, the 3’ part of the vector contained the Penk1 exon boundary of intron 1/exon
2 (including the splice acceptor site) fused to the open reading frame of the lacZ coding se-
quence. The 3’ end of the lacZ open reading frame was fused to a 1.5 kb fragment containing
the downstream region of the preproenkephalin gene. This also served as 3’ homology for
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Fig. 4.1: Targeted mutagenesis of the murine preproenkephalin locus. Depicted are the wild
type preproenkephalin locus (top) containing three exons, the targeting construct (center) and the
targeted gene locus (bottom). A neo gene (green) flanked by two loxP sites (pink triangle) and
the lacZ coding sequence (red) were inserted 3’ of the Penk1 wild type locus. A small fragment
containing the splice acceptor site of exon 2 was fused to the lacZ sequence. Upstream of exon 2
another loxP site was inserted. For electroporation in ES cells the targeting construct was linearized
via NotI digestion. Restriction sites used for Southern blot analysis plus the detectable fragments
(black StuI, brown XmaI ) using the Southern blot probe (purple) are indicated.
the recombination event in ES cells. Verification and amplification of this targeting construct
was done in previous experiments in the context of the diploma thesis “Untersuchungen am
endogenen Opioidsystem” (SCHÜRMANN, 2004).
The vector was linearized using NotI digestion prior to electroporation in ES cells. Within
the scope of this work four electroporations were performed resulting in∼ 2.1% of homologous
recombinant ES cell clones out of 475 harvested cells in total. The success of recombination
was verified by means of Southern blot analysis using StuI digestion. Since the 5’ loxP site
was only maintained if recombination occured distal to this loxP site, positive ES cell clones
were checked by XmaI digestion and Southern blot analysis for presence or abscense of this
loxP site. The expected fragments are depicted in figure 4.1. The existence of all three loxP
sites was demonstrated in one ES cell clone (H32). Southern blot results for two ES cell clones
after StuI and XmaI digestion are illustrated in figure 4.2. In clone H32, recombination occured
for the complete 5’ homolgy region demonstrated by the expected restriction patterns. These
patterns are presence of a 9.5 kb fragment (after XmaI digestion) and a 7 kb fragment (after StuI
digestion). Analysis of clone G17 also showed the 7 kb StuI fragment indicating a homologous
recombination event. However, in contrast to clone H32, in clone G17 only the wild type (wt)
fragment of 2.3 kb was detected after XmaI digestion.
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Fig. 4.2: Homologous recombinant ES cell clones. Southern blot analysis of ES cell DNA to
verify homologous recombination. Results of clone H32 and G17 are shown exemplary after StuI and
XmaI digestion. Both clones showed homologous recombination indicated by presence of the 7 kb
fragment after StuI digestion. Only in H32 recombination occurred distal to the 5’ loxP site as the
9.5 kb fragment was detected after XmaI digestion. For G17 only the XmaI wild type fragment of
2.3 kb was present.
4.1.2 Generation of conditional knockout mice
Injection of the homologous recombinant ES cell clone H32 into blastocysts derived from
C57BL/6J mice lead to highly chimeric mice that were predominantly males. The degree of
chimerism in these mice was evaluated by coat color, because the ES cell line used was derived
from agouti 129/Sv mice and the blastocyst from non-agouti C57BL/6J mice. Chimeric mice
were backcrossed to C57BL/6J females. The coat color revealed germline transmission, indi-
cated by agouti pups (Fig. 4.3A). In parallel, Southern blot analysis of mouse tail DNA proved
that the mutation was transmitted to the progeny, as digestion with StuI lead to the expected
Fig. 4.3: Germline transmission of clone H32. Offspring of chimeric mice generated by injection of
the homologous recombinant ES cell clone H32 in blastocysts. The coat color (A) as well as Southern
blot analysis after StuI digestion (B) revealed that the mutation was transmitted to progeny. The
alleles detected by Southern blot analysis are indicated (B). wt, wild type; lox, mutated gene locus.
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Fig. 4.4: Description of the mutated Penk1 gene locus. All possible allele combinations are
depicted. The Penk1 wild type locus (wt) consists of 3 exons. This locus was modified by the
introduction of 3 loxP sites (pink triangle), a lacZ (red) and a neo gene (green) named lox allele.
Cre recombinase-mediated recombination could result in different alleles depending on where recom-
bination occurs. The null mutant allele carrying lacZ as a reporter gene is named loxd, whereas the
modified locus after excision of the neo gene is designated as loxe. If only the neo cassette and the
lacZ reporter remained after cutting out the coding exons the allele is indicated as loxn.
fragments of 7 and 8.2 kb (Fig. 4.3B).
The resulting mouse line carried a floxed preproenkephalin locus as well as a floxed neo
gene on a mixed 129/Sv x C57BL/6J background. In these mice cre recombinase-mediated re-
combination could occur between all 3 loxP sites. Depending on the strength of cre recombinase
expression, this might lead to a mosaic pattern of cells carrying the different alleles illustrated
in figure 4.4 (loxe, loxd, loxn). For example recombination between the 1st and the 2nd loxP
site would lead to deletion of the enkephalin coding exons, but the floxed neo gene would be
present (loxn allele). In contrast, recombination between the 1st and the 3rd loxP site would
result in a knockout of exon 2 and 3 and excision of the neo gene. This directs lacZ expression
under the control of the endogenous enkephalin promoter (loxd allele). A third possible allele
could occur after excision of the neo gene subsequent to recombination between the 2nd and
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Fig. 4.5: Analysis of the offspring from Pgk-cre+/− x Penk1wt/lox matings. Exemplary
Southern blot results of StuI digested mouse tail DNA are shown. Presence of cre recombinase
expression (+) and the mutated Penk1 allele resulted in complete deletion of the floxed gene locus
as the loxd allele was present.
the 3rd loxP site (loxe allele). As the neo gene might additionally influence the stability and
expression of nearby genes, its excision is advisable.
The possibility of different recombination events was used to excise the neo gene. During
cre-mediated recombination varying alleles can occur simultaneously, also leading to the re-
quired loxe allele. Therefore mice carrying the lox allele were mated to Pgk-cre mice that are
known to produce ubiquitous expression of cre recombinase (LALLEMAND ET AL., 1998). In
this strain, cre recombinase expression is driven by the Pgk-1 promoter which is active during
early embryogenesis. The offspring of these matings were screened by Southern blot analy-
sis because StuI digestion would result in diverse fragments for all possible alleles (Fig. 4.4).
Exemplary outcome is depicted in figure 4.5. The presence of the cre recombinase transgene
Fig. 4.6: Analysis of the offspring from EIIa-cre+/+x Penk1wt/lox matings. Exemplary South-
ern blot results of StuI -digested mouse tail DNA are shown. Availability of cre recombinase expression
and the mutated Penk1 allele resulted in the presence of different allele combinations of the mutated
gene locus.
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always led to deletion of the entire floxed gene locus, indicated by the presence of the loxd
allele.
As mating of Pgk-cre+/− and Penk1wt/lox did not provide the expected results, another cre
recombinase expressing mouse strain was used. EIIa-cre mice carry the cre transgene under
the control of the adenovirus EIIa promoter. This promoter also targets expression of cre re-
combinase to early mouse development (LAKSO ET AL., 1996). Analysis of the progeny of
EIIa-cre+/+ x Penk1wt/lox matings revealed that multiple alleles were present in a single mouse
(Fig. 4.6). One mouse labeled wt/mix in figure 4.6 even showed all possible fragments after
StuI digestion, indicating presence of all allele combinations (wt 8.2 kb, lox 7 kb, loxe 11.6 kb,
loxd 6 kb, loxn 1.7 kb).
This Penk1wt/mix mouse was mated to C57BL/6J mice to obtain animals carrying either the
loxe or the loxd allele. These animals were further backcrossed to C57BL/6J animals to es-
tablish two mouse lines that can be used in parallel. Namely, one constitutive knockout strain
Penk1loxd/loxd expressing ß-galactosidase under the control of the endogenous enkephalin pro-
moter and a second strain carrying a floxed preproenkephalin gene locus (Penk1loxe/loxe). Mice
of both strains were backcrossed to C57BL/6J animals to obtain congenic mice. In general a
congenic background is established after mating for 10 generations. During this thesis the mice
were backcrossed for 9 (Penk1loxe/loxe) or for 8 (Penk1loxd/loxd) generations.
4.1.3 Quantitative expression analysis
At first, expression levels of Penk1lox/lox mice were evaluated by quantitative real time PCR.
Analysis of expression data from striatal mRNA preparations revealed a significant genotype
effect depending on the lox allele [F2,14 = 4.38, p = 0.038] (Fig. 4.7A). In mice homozygous
Fig. 4.7: Expression of enkephalin in the striatum. Preproenkephalin mRNA levels normalized to
ß-actin were compared between either wt, heterozygous, or mice homozygous for the mutated Penk1
allele. (A) In Penk1 lox/lox mice (n=3) post hoc comparison revealed a significant reduction in RNA
levels compared to their wild type counterparts (n=3). (B) A significant difference was also detected
between Penk1 loxe/loxe (n=4), Penk1wt/loxe(n=6) or Penk1wt/wt mice (n=4). Values represent
mean ± SEM whereas the mean of wild type mice was set to 100%. Significance thresholds are *p
< 0.5, **p < 0.01 (Bonferroni post hoc test).
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for the lox allele, mRNA levels were significantly reduced by 20% compared to their wild type
littermates. Thus, the genetic modification had an impact on enkephalin expression. There was
no significant difference in the direct comparison of heterozygous Penk1wt/lox and homozygous
Penk1lox/lox or Penk1wt/wt animals. After establishing the Penk1loxe/loxe strain by deletion of
the neo gene (see subsection 4.1.2), the mRNA levels were measured in these mice. The loxe
allele also influenced preproenkephalin mRNA levels [F2,13 = 13.65, p = 0.001]. There was a
significant reduction of 20% between Penk1wt/wt and Penk1loxe/loxe and a reduction of 16% in
Penk1loxe/loxe compared to Penk1wt/loxe (Fig. 4.7).
Fig. 4.8: Different splice variants of the preproenkephalin gene. The alternative splicing of
preproenkephalin RNA can lead to two different transcripts. One transcript contained three exons
(A) and the other contained two exons (B). The coding region (indicated by red boxes) did not differ
between these transcript, but the 5’UTR was changed.
A second transcript of Penk1 consisting of two exons instead of three was recently annotated in
public databases (Fig. 4.8). In this second transcript (ENSMUST00000070375) exon 2 is iden-
tical to exon 3 of ENSMUST00000108381, whereas the first coding exon differs. Thereby the
5’ loxP site introduced into the Penk1 locus is located in the 5’ UTR of the new annotated tran-
script. It was evaluated if the genetic modification introduced into the Penk1 locus influences
the expression or the stability of the different transcripts. Therefore transcript-specific assays
were used. For transcript ENSMUST00000070375, mRNA levels were significantly decreased
in mice carrying one or two copies of the loxe allele [F2,13 = 24.70, p < 0.0001], whereby mice
homozygous for loxe showed a reduction of 72% compared to their wild type littermates (Fig.
4.9A). Unexpectedly, a similar result was observed for transcript ENSMUST00000108381 in
which the loxP site is located upstream of exon 2 [F2,13 = 18.00, p = 0.003] (Fig. 4.9C). The
total level of Penk1 mRNA is reduced by 70% in Penk1loxe/loxe animals. In Penk1wt/loxd mice
enkephalin mRNA levels were reduced to 50%, meaning that homozygous loxe mice had less
mRNA than heterozygous knockout animals (Fig. 4.9B,D). None of the two transcripts was
detected in Penk1loxd/loxd animals and for both transcripts a significant genotype effect depend-
ing on the loxd allele was observed (ENSMUST00000070375 [F2,11 = 138.4, p < 0.0001],
ENSMUST00000108381 [F2,11 = 32.84, p < 0.0001]).
Quantitative PCR was also performed for preprodynorphin mRNA in order to check if reduction
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Fig. 4.9: Expression of all enkephalin coding transcripts in the striatum. mRNA levels of
transcript ENSMUST00000070375 were altered depending on the Penk1 genotype. The loxe allele led
to a significant reduction in expression levels (A), and after deletion of the coding exons there was no
preproenkephalin detectable (B). Similar results were observed for transcript ENSMUST00000108381
for the loxe (C) or loxd (D) allele. Transcript levels of Pdyn RNA that can give rise to Leu-enkephalin
were independent of the allelic status of the Penk1 gene locus (E),(F). Values represent mean ±
SEM, whereas the mean of wild type mice was set as 100%. Significance thresholds are *p < 0.5,
**p < 0.01, ***p < 0.001 (Bonferroni post hoc test). Penk1wt/wt n = 4, Penk1wt/loxe n = 6,
Penk1 loxe/loxe n = 4, Penk1wt/loxd n = 4, Penk1 loxd/loxd n = 4.
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in enkephalin mRNA causes a compensatory up-regulation, as it was suggested that one copy
of Leu-enkephalin is derived from the dynorphin precursor protein (DAY ET AL., 1998). No
significant genotype effect was observed for the loxe [F2,13 = 0.20, p = ns] or for the loxd allele
[F2,11 = 0.99, p = ns] (Fig.4.9), not indicating compensatory up-regulation of preprodynorphin.
Fig. 4.10: Met- and Leu-enkephalin levels in mice carrying different Penk1 alleles. Met-
(A) and Leu-enkephalin (B) levels were changed as a function of the genotype. Amounts of both
enkephalins were significantly reduced in Penk1 loxe/loxe versus Penk1wt/wt mice. However, the
enkephalin levels in Penk1 loxe/loxe mice still differed significantly compared to Penk1 loxd/loxd ani-
mals. In these mice, Met- enkephalin was absent, while < 50% of the Leu-enkephalin was detected.
Values represent mean ± SEM. Significance thresholds are *p < 0.5, **p < 0.01, ***p < 0.001
(Bonferroni post hoc test). Penk1wt/wt n = 2, Penk1 loxe/loxe n = 3, Penk1 loxd/loxd n = 3.
Radioimmunoassays for Met- and Leu-enkephalin were performed to reveal if the differences
in expression levels are reflected by the amount of enkephalin peptides. Significant geno-
type effects were observed for Met-enkephalin [F2,7 = 173.5, p < 0.0001] as well as for Leu-
enkephalin [F2,7 = 27.67, p = 0.002]. In Penk1loxe/loxe mice, only 1/3 of the Met-enkephalin
peptide of wild type littermates was found (Fig. 4.10A). As expected, Met-enkephalin was ab-
sent in Penk1loxd/loxd animals, whereas approximately half of the Leu-enkephalin was left (Fig.
4.10B). This was probably derived from the preprodynorphin precursor protein. The reduction
of enkephalin levels in homozygous loxe mice thus mirrored the reduced amount of mRNA.
The concentration of Met-enkephalin was higher compared to Leu-enkephalin, except for the
homozygous knockout mice (Fig. 4.10A,B).
4.1.4 Qualitative expression analysis
In situ hybridization was conducted to detect preproenkephalin mRNA on brain slices. A pBlue-
script SK vector containing a DNA fragment with exon 3 of the Penk1 gene was used as tem-
plate for production of the in situ-probe. Because the antisense probe was directed against the
sequence of exon 3, both possible transcripts were detected. There was pronounced expres-
sion of enkephalin in the striatum of Penk1lox/lox mice (Fig. 4.11). In contrast, no enkephalin
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Fig. 4.11: Preproenkephalin expression in the striatum. In situ hybridization revealed marked
expression of enkephalin in the striatum (CPu) of Penk1 lox/lox mice, whereas expression was missing
after deletion of the coding exons (Penk1 loxd/loxd). The absence of signal after application of the
sense probe proved its specificity. cc, corpus callosum; CPu, caudate putamen; LV, lateral ventricle.
mRNA was detectable in the null allele mice (Penk1loxd/loxd), which is in line with the quan-
titative expression data. This result, together with the absence of signal using the sense probe,
also proved the high specificity of the in situ probe.
The lacZ gene was introduced in the mutated gene locus to function as a reporter gene. Sub-
sequent to the deletion of the enkephalin coding region it should be expressed under the control
of the endogenous enkephalin promoter. X-gal staining on brain slides of Penk1loxd/loxd mice
was performed to assess ß-galactosidase activity. Staining was detected in all brain regions that
normally express preproenkephalin. Two prominent regions of enkephalin expression are the
striatum, especially the nucleus accumbens (NAc), and the central amygdala (CeA). Exemplary
results of staining in these regions are illustrated in figure 4.12.
Fig. 4.12: ß-galactosidase activity in Penk1 loxd/loxd mice. An exemplary X-gal staining in
Penk1 loxd/loxd mice is shown. Deletion of the enkephalin coding exons led to ß-galactosidase ex-
pression and activity in regions of former enkephalin expression like the nucleus accumbens (NAc)
and the central amygdala (CeA). aca, anterior comissure,anterior; Bla, basolateral amygdala; CeA,
central amygdala; NAc, nucleus accumbens.
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4.1.5 Behavioral phenotyping
As described in subsection 4.1.3, there is a reduction in enkephalin expression as well as in
Met- and Leu-enkephalin levels in mice homozygous for the loxe allele. To evaluate possible
behavioral consequences these mice were studied in the zero maze test, which is an animal
model for anxiety. The anxiety phenotype of constitutive Penk1 knockout was very robust in
this test.
Fig. 4.13: Zero maze behavior. Anxiety levels depending on the Penk1 allele were assessed
by time spent in the open area (A), distance traveled in the open area (B) and latency to enter
the closed area of the maze (C). Only the latency values differed significantly between Penk1wt/wt
and Penk1 loxe/loxe animals. Values represent mean ± SEM. Significance thresholds are *p < 0.5
(Bonferroni post hoc test). Penk1wt/wt n = 11, Penk1wt/loxe n = 9, Penk1 loxe/loxe n = 11.
There was no genotype effect on the time spent in the open area [F2,30 = 1.15, p = ns] nor on
the distance traveled in the open part of the maze [F2,30 = 1.90, p = ns]. However, the latency to
enter the closed area differed significantly dependent on the genotype [F2,26 = 4.19], p = 0.027].
In Penk1loxe/loxe mice the latency was increased, which was significant in direct comparison to
Penk1wt/wt animals (Fig. 4.13).
4.1.6 Viral injection into the nucleus accumbens
The floxed preproenkephalin mice were generated to provide a tool that enables a tissue- or
region-specific knockout of enkephalin. A region-specific knockout can be achieved by the
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Fig. 4.14: Knockout of enkephalin after viral injection. In situ hybridization results of consec-
utive brain sections are presented. Signals for preproenkephalin mRNA were absent subsequent to
injection of an adeno-associated virus expressing cre recombinase of Penk1 lox/lox mice (red circles;
B,C,D). The knockout of enkephalin was restricted to the injection site. In contrast, injection of
adeno-associated viruses expressing GFP did not influence preproenkephalin mRNA (A). cc, corpus
callosum; CPu, caudate putamen.
injection of cre recombinase-expressing viruses into distinct brain regions. To elucidate the
efficacy of virus-mediated knockout, a cre recombinase-expressing adeno-associated virus was
injected into the striatum of Penk1lox/lox mice. The results were evaluated by in situ hybridiza-
tion. The lack of preproenkephalin mRNA at the injection site indicated a definite knockout of
enkephalin after viral injection (Fig. 4.14).
It was a major focus of the present work to investigate the role of endogenous opioid pep-
tides in drug addiction. Since dopamine signaling in the NAc is a key regulator of addiction
Fig. 4.15: Viral injection in the nucleus accumbens. Confocal images of brain slides are shown.
Mice received a single injection of eGFP-expressing adeno-associated viruses (AAVs) at 1.2 mm
(anteroposterior), 1.0 mm (mediolateral), 3.6 mm (dorsoventral) according to bregma to target
the nucleus accumbens. GFP staining was observed at the injection site. GFP was not expressed
contralateral to the injection site. aca, anterior commissure anterior; AcbC, nucleus accumbens
core; AcbSh, nucleus accumbens shell; CPu, caudate putamen; LAcbSh, lateral accumbens shell; LV,
lateral ventricle.
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processes, this region was the first target for the regional deletion of enkephalin. To illustrate
the targeting of the nucleus accumbens, eGFP-expressing AAV2 viruses were injected into one
brain hemisphere of wild type mice. As shown in figure 4.15, a specific eGFP staining in the
NAc was detectable only at the injection site.
Like many other drugs of abuse, nicotine administration leads to an increase in dopamine lev-
els in the NAc. This nicotine-dependent increase was attenuated in constitutive Penk1−/− mice.
Additionally, these mice exhibited no nicotine-induced conditioned place preference (BERREN-
DERO ET AL., 2005), suggesting that nicotine is not rewarding for them. One mechanism
underlying this phenotype might be the modulation of dopamine release via enkephalinergic
projections from the NAc to the VTA. Specific knockout of enkephalin in the NAc was used to
elucidate the role of enkephalin in this process. Therefore GFP expressing AAVs (control) or cre
recombinase expressing AAVs were injected into the NAc of Penk1loxe/loxe mice. These mice
were then analyzed for nicotine self-administration in the laboratory of Prof. R. Maldonado
(Barcelona, Spain).
Fig. 4.16: Nicotine self-administration. Subsequent to surgery, mice were analyzed in an operant
model to examine nicotine self-administration. Mice received injections of either cre recombinase-
or eGFP-expressing adeno-associated viruses to target the nucleus accumbens. Illustrated are the
nose pokes per 1h for the active and the inactive sensor. No difference was observed either in the
acquisition (A) or in the extinction (B) phase. Acquisition CRE n = 8, GFP n = 8; extinction CRE
n = 8, GFP n = 7.
In a first experiment, 18 mice (10 females, 8 males) were injected with eGFP-AAV and 19 mice
(9 females, 10 males) with Cre-AAV. The results of the subsequent nicotine self-administration
experiment are depicted in figure 4.16. The time needed to achieve the self-administration
acquisition criteria did not differ between the groups. All mice discriminated between the active
and inactive holes and an increase in the number of active nose-poking responses was seen
independent of the injected virus (Fig. 4.16A). Repeated-measures two way ANOVA revealed
a significant effect for factor discrimination, time and the interaction term [F1,26 = 22.25, p <
0.0001 for factor discrimination; F9,234 = 10.44, p < 0.00001 for factor time; F9,234 = 7.79, p
< 0.00001 for discrimination x time]. No genoytpe effect was detected [F1,26 = 2.22, p = ns].
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During the extinction phase, no significant difference was observed between Cre-AAV or GFP-
AAV-injected animals [F1,16 = 0.28, p = ns]. Time to achieve the extinction criteria and the
number of active or inactive nose-poking were similar in both groups. During the first extinction
session, all mice showed an enhancement in the number of responses (active sensor) compared
to the last day of self-administration training. At the end of the extinction phase discrimination
between the holes vanished [F19,304 = 139.95, p < 0.00001 for discrimination x time].
4.2 SNP genotyping
In this section, the results of the human association studies are described. Polymorphisms
in human genes coding for preproenkephalin, proopiomelanocortin as well as preprodynorphin
were evaluated for frequency differences between controls and alcohol-dependent subjects. This
analysis was conducted to investigate the contribution of variants in genes coding for opioid
peptides to alcohol dependence in humans.
4.2.1 Exploratory analysis
When the initial genotyping was started, no linkage disequillibrium data for the genes coding for
endogenous opioid peptides were available. Markers were chosen to cover a region of around
20 kb surrounding the corresponding gene locus. For the human preproenkepahlin gene locus,
which maps to chromosome 8q23-q24, five markers were selected, whereas one marker was
located downstream, one was intronic and three markers were located upstream of the coding
region (Fig. 4.17). The human gene coding for proopiomelanocortin maps to chromosome
2p23.3. Here, initially three SNPs were selected, later one had to be excluded due to inadequate
clustering of the genotypes. For all gene loci, locations of the finally genotyped markers are
shown in figure 4.17. One marker lay upstream and one downstream of the transcribed region.
Tab. 4.1: SNPs major allele frequency and association with alcohol dependence for the exploratory
genotyping.
Gene Marker SNP Controls Cases p (Armitage)
PENK rs8181029 C\T .58 .60 .557
PENK rs6474063 T\C .68 .69 .926
PENK rs1975285 C\G .76 .76 .916
PENK rs2576576 G\A .67 .61 .088
PENK rs2576581 G\A .55 .55 .991
POMC rs1866146 C\G .68 .65 .349
POMC rs874401 G\A .80 .84 .313
PDYN rs910080 A\G .73 .69 .267
PDYN rs2235754 C\T .65 .62 .422
PDYN rs6045920 C\A .85 .84 .639
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Fig. 4.17: Location of markers used for initial genotyping of the human opioid peptide genes.
The gene coding for preproenkephalin (PENK ) has a size of ∼ 5 kb and is located on chromosome 8.
The gene for proopiomelanocortin (POMC ) is mapped to chromosome 2 with a size of approximately
8 kb. On chromosome 20, the PDYN gene (coding for preprodynorphin) is sited, which spans around
15 kb. The direction of transcription is indicated by an arrow.
Figure 4.17 also illustrates the allocation of markers throughout the human preprodynorphin
gene locus on chromosome 20pter-p12.2.
Genotype distributions for all polymorphisms were consistent with HWE expectations in
both groups. However, no significant frequency difference among cases and controls was ob-
served. For marker rs2576581, located upstream of PENK, the A allele was more frequent in
cases but this failed to reach significance (p = 0.088). All allele frequencies and p-values are
listed in table 4.1.
4.2.2 Detailed genotyping
An in depth genotyping was performed based on results obtained from in-house behavioral
analysis of knockout mouse strains for Penk1, ß-endorphin (encoded by Pomc) and Pdyn and
based on the frequency difference observed for marker rs2576581. In addition to an increased
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Fig. 4.18: Location and linkage disequilibrium of single nucleotide polymorphisms (SNPs).
The gene structure of the human PENK, POMC and PDYN locus and the location of the analyzed
SNPs are indicated. The coding regions are plotted in orange. For all three genes the negative
strand is the transcription template. Linkage disequilibrium (LD) was calculated on the basis of
the German control group. LD-plots were generated with Haploview using the Gold-heatmap color
scheme, whereas 1 reflects strong linkage. Black triangles represent predicted haplotype blocks. The
direction of transcription is indicated by an arrow.
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number of cases, a different control sample that was designed to serve as an epidemiological
control sample in the context of the NGFN was provided. The use of this cohort allowed
the precise match of cases and controls in terms of gender and age. Linkage disequilibrium
and haplotype data for all three genes (based on a reference population) was available at the
International HapMap project (Phase II). The data were extracted and appropriate tagging SNPs
were chosen to cover the genomic regions of interest.
For PENK, all five predicted tagging SNPs that covered a haplotype block of 92 kb
(HapMap) encompassing the two exons were genotyped. For marker rs10108778 genotyp-
ing signals were not grouped into well-defined clusters. Therefore genotyping data for this
marker were excluded from the analysis. The SNP rs12545109 is located 40 kb downstream of
exon 2, and rs2670029 is 26 kb upstream of the transcription initiation site (Fig. 4.18). Based
on the LD structure of German control subjects, one haplotype block for markers rs2576581,
rs12548084, and rs2670029 was indicated (Fig. 4.18). This block corresponds to the haplotype
block predicted by HapMap data for Caucasian populations. In contrast, markers at the POMC
gene locus showed weak LD in Caucasians. Therefore, nine SNPs with an even spacing of
approximately 3 kb extending from 11 kb upstream of exon 1 up to 6 kb downstream from exon
3 were selected (Fig. 4.18). In accordance with HapMap data, only weak LD between markers
was detected in the German control group. Regarding the PDYN gene locus, markers which
captured all common haplotypes at a frequency > 5 % in a Caucasian reference population
were genotyped. At the same time Xuei and coworkers reported evidence for significant asso-
ciation of PDYN SNPs with alcoholism in the COGA cohort (XUEI ET AL., 2006). Therefore
markers presented in their study were included for genotyping. This led to an overall number of
16 PDYN polymorphisms analyzed in the present study. Based on results of all PDYN markers
in the German control group, calculation of the haplotype structure revealed three haplotype
blocks that resemble those predicted by HapMap. The strongest LD was observed in the 3’ part
of PDYN leading to an haplotype block of around 18 kb (Fig. 4.18).
The analysis of Penk1, ß-endorphin and Pdyn knockout mice revealed gender-specific differ-
ences in alcohol-related behaviors, therefore the allele and genotype distributions were evalu-
ated in the entire sample as well as separately in the female and male subgroups. In the German
sample, all markers showed expected allele frequencies (Tab. 4.2 and Tab. 4.4) and revealed
no significant deviation from HWE (p > 0.05) (Appendix). The unadjusted p-values for allele
frequencies of rs12545109 (p = 0.031, OR = 0.73) and rs2576581 in females (p = 0.007, OR =
1.84) (Tab. 4.2) suggested association with the disease phenotype. Both SNPs also showed low
p-values for genotype distributions between alcoholic patients and control subjects in the whole
sample or the female subgroup, respectively (Tab. 4.3).
After Bonferroni correction for multiple testing, only marker rs2576581 remained below
the 5% significance threshold (allele distribution corrected p = 0.028; Armitage’s Trend Test
corrected p = 0.036). For rs2164808 and rs934778, which are located upstream of the POMC
4.2. SNP GENOTYPING 54
Tab. 4.2: PENK and POMC SNPs major allele frequency and association with alcohol dependence
in the German sample.
Gene Marker SNP
Genomic
Sample
Control
Cases pc OR CId
Locationa Subjectsb
PENK rs12545109 C\A 57476460 All .773 .712 .031 .729 [.546–.972]
C\A Femalee .769 .708 .260 .729 [.420–1.265]
C\A Male .774 .712 .060 .723 [.515–1.014]
PENK rs2576581 G\A 57528504 All .515 .568 .094 1.242 [.963–1.602]
G\A Female .418 .586 .007 1.971 [1.206–3.222]
G\A Male .552 .565 .729 1.054 [.782–1.422]
PENK rs12548084 C\T 57540810 All .946 .945 .924 .973 [.560–1.694]
C\T Female .948 .954 .820 1.139 [.372–3.485]
C\T Male .946 .941 .800 .921 [.486–1.745]
PENK rs2670029 C\A 57547550 All .569 .606 .239 1.165 [.903–1.503]
C\A Female .478 .585 .082 1.539 [.946–2.504]
C\A Male .603 .615 .759 1.048 [.776–1.415]
POMC rs2164808 G\A 25230680 All .557 .496 .056 1.276 [.993–1.640]
G\A Female .612 .462 .014 1.840 [1.128–3.002]
G\A Male .536 .506 .413 1.130 [.843–1.515]
POMC rs7589318 G\A 25231876 All .678 .651 .368 .885 [.679–1.154]
G\A Female .701 .600 .084 .638 [.383–1.063]
G\A Male .669 .668 .956 .992 [.727–1.353]
POMC rs1866146 T\C 25234077 All .670 .669 1.000 .997 [.764–1.301]
T\C Female .664 .636 .635 .885 [.534–1.465]
T\C Male .672 .683 .767 1.049 [.766–1.435]
POMC rs6713532 T\C 25238337 All .771 .798 .308 1.171 [.864–1.588]
T\C Female .739 .754 .779 1.083 [.622–1.886]
T\C Male .783 .816 .280 1.224 [.848–1.765]
POMC rs934778e T\C 25242728 All .692 .732 .088 1.217 [.971–1.525]
T\C Female .693 .786 .004 1.629 [1.165–2.279]
T\C Male .690 .685 .896 .979 [.713–1.344]
POMC rs3769671e A\C 25243657 All .967 .974 .404 1.298 [.701–2.403]
A\C Female .974 .970 .725 3.969 [.487–2.812]
A\C Male .957 .978 .124 1.959 [.820–4.681]
POMC rs6545976 G\T 25248154 All .967 .959 .489 .790 [.404–1.543]
G\T Female .970 .961 .683 .757 [.199–2.884]
G\T Male .966 .958 .566 .798 [.368–1.729]
POMC rs6719226 C\G 25249516 All .966 .959 .571 .827 [.428–1.598]
C\G Female .970 .961 .683 .757 [.199–2.884]
C\G Male .964 .958 .666 .847 [.397–1.806]
POMC rs874401 C\T 25255784 All .812 .837 .303 1.189 [.855–1.652]
C\T Female .791 .800 .856 1.057 [.581–1.922]
C\T Male .819 .852 .240 1.268 [.853–1.885]
a Genomic location is based on National Center for Biotechnology Information (NCBI) human genome assembly B36.
b The allele frequency is shown for the left allele.
c Uncorrected p-value of FAMHAP statistic for allele frequency differences between cases and controls.
d 95% confidence interval.
e Note that the sample size is different for these markers.
Significance is indicated in bold.
gene and inside intron 1, respectively, differences for allele and genotype distributions between
German female alcoholic patients and control subjects were detected (Tab. 4.2 and Tab. 4.3).
However, after Bonferroni correction, only marker rs934778 showed a significant association
in German females (allele distribution corrected p = 0.036; Armitage’s Trend Test corrected p =
0.027).
In the case of PDYN, a few markers revealed significant frequency differences on an allelic
level between female cases and controls only. Here, unadjusted p-values for SNP rs2235749,
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Tab. 4.3: PENK and POMC SNPs genotype distribution and association with alcohol dependence
in the German sample.
Gene Marker Sample Control Subjects Cases
p p
(Global)a (Armitage)b
PENK rs12545109 All CC=148 AC=81 AA=15 CC=126 AC=97 AA=22 .104 .035
Female CC=39 AC=25 AA=3 CC=33 AC=26 AA=6 .475 .260
Male CC=109 AC=56 AA=12 CC=92 AC=71 AA=16 .152 .068
PENK rs2576581 All GG=63 AG=120 AA=56 GG=85 AG=104 AA=52 .103 .104
Female GG=11 AG=34 AA=22 GG=24 AG=27 AA=13 .019 .009
Male GG=52 AG=86 AA=34 GG=61 AG=77 AA=38 .499 .736
PENK rs12548084 All CC=218 CT=22 TT=2 CC=218 CT=27 TT=0 .288 .924
Female CC=60 CT=7 TT=0 CC=59 CT=6 TT=0 .815 .815
Male CC=158 CT=15 TT=2 CC=158 CT=21 TT=0 .228 .805
PENK rs2670029 All CC=78 AC=124 AA=44 CC=93 AC=111 AA=41 .343 .242
Female CC=13 AC=38 AA=16 CC=22 AC=32 AA=11 .155 .072
Male CC=65 AC=86 AA=28 CC=71 AC=78 AA=30 .696 .764
POMC rs2164808 All GG=75 AG=125 AA=47 GG=65 AG=113 AA=67 .090 .060
Female GG=24 AG=34 AA=9 GG=15 AG=30 AA=20 .039 .015
Male GG=51 AG=91 AA=38 GG=49 AG=83 AA=47 .507 .420
POMC rs7589318 All GG=117 AG=101 AA=29 GG=110 AG=99 AA=36 .612 .388
Female GG=33 AG=28 AA=6 GG=26 AG=26 AA=13 .178 .099
Male GG=84 AG=73 AA=23 GG=83 AG=73 AA=23 .999 .956
POMC rs1866146 All TT=117 CT=97 CC=33 TT=113 CT=102 CC=30 .848 1.000
Female TT=28 CT=33 CC=6 TT=26 CT=32 CC=8 .832 .621
Male TT=89 CT=64 CC=27 TT=87 CT=69 CC=22 .701 .783
POMC rs6713532 All TT=151 CT=79 CC=17 TT=158 CT=75 CC=12 .572 .326
Female TT=37 CT=25 CC=5 TT=36 CT=26 CC=3 .778 .777
Male TT=114 CT=54 CC=12 TT=122 CT=48 CC=9 .592 .306
POMC rs934778 All TT=195 CT=191 CC=34 TT=178 CT=130 CC=24 .146 .082
Female TT=107 CT=120 CC=14 TT=97 CT=45 CC=10 .0004 .003
Male TT=88 CT=71 CC=20 TT=80 CT=84 CC=14 .283 .896
POMC rs3769671 All AA=382 AC=25 CC=1 AA=314 AC=17 CC=0 .561 .409
Female AA=221 AC=12 CC=0 AA=141 AC=9 CC=0 .722 .722
Male AA=161 AC=13 CC=1 AA=171 AC=8 CC=0 .294 .134
POMC rs6545976 All GG=228 GT=16 TT=0 GG=223 GT=20 TT=0 .480 .480
Female GG=63 GT=4 TT=0 GG=59 GT=5 TT=0 .677 .677
Male GG=165 GT=12 TT=0 GG=163 GT=15 TT=0 .558 .558
POMC rs6719226 All CC=231 CG=15 GG=1 CC=222 CG=20 GG=0 .398 .575
Female CC=63 CG=4 GG=0 CC=59 CG=5 GG=0 .677 .677
Male CC=168 CG=11 GG=1 CC=162 CG=15 GG=0 .428 .671
POMC rs874401 All CC=165 CT=71 TT=11 CC=173 CT=64 TT=8 .601 .316
Female CC=41 CT=24 TT=2 CC=43 CT=18 TT=4 .463 .858
Male CC=124 CT=47 TT=9 CC=130 CT=45 TT=4 .349 .255
a Uncorrected p-value of FAMHAP statistic for association between SNPs and alcohol dependence.
b p-value of the Armitage’s trend test.
Significance is indicated in bold.
rs910080, rs6045819, rs6045824, rs6035253 were below the 5% significance threshold. An
odds ratio < 1 indicated a protective effect of the major allele for these markers (Tab.4.4).
Four of these markers (rs2235749, rs910080, rs6045824, rs6035253) also differed signifi-
cantly in their genotype frequency among female cases and controls (Tab. 4.5). However, only
for rs910080 and rs6035235, the global genotype as well as the Armitage p-value was signif-
icant. Another two markers showed association in the female subgroup only on a genotype
level (rs6045733 and rs6035222). For rs6035222 a significant difference in genotype distribu-
tions was detected in the whole sample as well (Tab. 4.5). However, subsequent to Bonferroni
correction none of the markers remained significant.
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Tab. 4.4: PDYN SNPs major allele frequency and association with alcohol dependence in the
German sample.
Gene Marker SNP
Genomic
Sample
Control
Cases pc OR CId
Locationa Subjectsb
PDYN rs6112177 C\A 1897127 All .814 .798 .531 .904 [.659-1.240]
C\A Female .843 .795 .310 .723 [.385-1.356]
C\A Male .803 .798 .867 .969 [.672-1.398]
PDYN rs6045733 G\A 1898858 All .642 .61 .300 .872 [.674-1.129]
G\A Female .687 .59 .098 .656 [.397-1.083]
G\A Male .625 .615 .787 .959 [.709-1.297]
PDYN rs6045761 A\G 1901363 All .883 .88 .888 .972 [.660-1.433]
A\G Female .933 .875 .111 .504 [.214-1.186]
A\G Male .864 .881 .502 1.163 [.748-1.808]
PDYN rs6045784 T\C 1904663 All .885 .875 .643 .913 [.621-1.342]
T\C Female .933 .864 .062 .456 [.197-1.056]
T\C Male .867 .879 .635 1.113 [.716-1.729]
PDYN rs2235749 G\A 1907939 All .719 .697 .459 .901 [.685-1.186]
G\A Female .799 .679 .026 .534 [.306-.932]
G\A Male .689 .702 .698 1.065 [.775-1.465]
PDYN rs910080 A\G 1908226 All .727 .711 .592 .927 [.702-1.224]
A\G Female .806 .679 .018 .509 [.291-.893]
A\G Male .697 .722 .467 1.127 [.816-1.557]
PDYN rs10485703 A\G 1908313 All .883 .876 .752 .940 [.641-1.379]
A\G Female .933 .866 .068 .464 [.200-1.074]
A\G Male .864 .879 .540 1.147 [.740-1.778]
PDYN rs6045819 A\G 1909134 All .885 .869 .467 .868 [.593-1.271]
A\G Female .933 .856 .041 .428 [.186-.985]
A\G Male .867 .874 .783 1.063 [.688-1.644]
PDYN rs6045824 T\C 1909977 All .886 .871 .479 .871 [.593-1.278]
T\C Female .94 .862 .032 .395 [.165-.944]
T\C Male .866 .874 .739 1.077 [.696-1.666]
PDYN rs6035222 G\A 1911413 All .877 .852 .254 .809 [.561-1.165]
G\A Female .925 .851 .053 .46 [.206-1.024]
G\A Male .858 .851 .784 .944 [.623-1.43]
PDYN rs6035235 T\G 1915155 All .889 .871 .405 .849 [.578-1.248]
T\G Female .94 .854 .020 .371 [.156-.881]
T\G Male .869 .877 .758 1.072 [.690-1.664]
PDYN rs12480838 C\T 1917824 All .844 .837 .753 .947 [.672-1.333]
C\T Female .881 .815 .140 .599 [.302-1.188]
C\T Male .831 .844 .634 1.102 [.740-1.641]
PDYN rs2235751 A\G 1917934 All .753 .730 .420 .888 [.666-1.184]
A\G Female .766 .731 .523 .833 [.476-1.458]
A\G Male .749 .729 .544 .901 [.645-1.261]
PDYN rs3830064 A\C 1923679 All .844 .830 .546 .901 [.643-1.264]
A\C Female .873 .806 .134 .604 [.310-1.174]
A\C Male .833 .838 .867 1.034 [.697-1.535]
PDYN rs7272891 C\G 1924818 All .915 .912 .862 .962 [.616-1.5]
C\G Female .896 .909 .709 1.167 [.518-2.627]
C\G Male .922 .912 .635 .879 [.515-1.498]
PDYN rs10854244 A\T 1925045 All .755 .728 .326 .867 [.651-1.153]
A\T Female .761 .709 .333 .764 [.443-1.318]
A\T Male .753 .733 .548 .902 [.645-1.262]
a Genomic location is based on National Center for Biotechnology Information (NCBI) human genome assembly B36.
b The allele frequency is shown for the left allele.
c Uncorrected p-value of FAMHAP statistic for allele frequency differences between cases and controls.
d 95% confidence interval.
Significance is indicated in bold.
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Tab. 4.5: PDYN SNPs genotype distribution and association with alcohol dependence in the
German sample.
Gene Marker Sample Control Subjects Cases
p p
(Global)a (Armitage)b
PDYN rs6112177 All CC=163 AC=76 AA=8 CC=155 AC=81 AA=9 .814 .527
Female CC=48 AC=17 AA=2 CC=40 AC=25 AA=1 .276 .294
Male CC=115 AC=59 AA=6 CC=114 AC=56 AA=8 .837 .867
PDYN rs6045733 All GG=106 AG=105 AA=36 GG=85 AG=130 AA=31 .069 .296
Female GG=34 AG=24 AA=9 GG=19 AG=41 AA=7 .011 .09
Male GG=72 AG=81 AA=27 GG=65 AG=89 AA=24 .638 .786
PDYN rs6045761 All AA=195 AG=46 GG=6 AA=185 AG=54 GG=2 .243 .89
Female AA=59 AG=7 GG=1 AA=49 AG=14 GG=1 .203 .124
Male AA=136 AG=39 GG=5 AA=135 AG=40 GG=1 .267 .503
PDYN rs6045784 All TT=196 CT=45 CC=6 TT=185 CT=57 CC=2 .156 .646
Female TT=59 CT=7 CC=1 TT=49 CT=16 CC=1 .109 .068
Male TT=137 CT=38 CC=5 TT=135 CT=41 CC=1 .25 .635
PDYN rs2235749 All GG=133 AG=89 AA=25 GG=117 AG=109 AA=20 .165 .465
Female GG=45 AG=17 AA=5 GG=29 AG=33 AA=5 .014 .029
Male GG=88 AG=72 AA=20 GG=87 AG=76 AA=15 .665 .701
PDYN rs910080 All AA=136 AG=87 GG=24 AA=123 AG=104 GG=19 .253 .599
Female AA=45 AG=18 GG=4 AA=29 AG=33 GG=5 .018 .018
Male AA=91 AG=69 GG=20 AA=93 AG=71 GG=14 .578 .478
PDYN rs10485703 All AA=195 AG=46 GG=6 AA=187 AG=57 GG=2 .188 .753
Female AA=59 AG=7 GG=1 AA=50 AG=16 GG=1 .119 .075
Male AA=136 AG=39 GG=5 AA=136 AG=41 GG=1 .258 .54
PDYN rs6045819 All AA=195 AG=47 GG=5 AA=183 AG=60 GG=2 .198 .465
Female AA=59 AG=7 GG=1 AA=48 AG=17 GG=1 .071 .046
Male AA=136 AG=40 GG=4 AA=134 AG=43 GG=1 .384 .78
PDYN rs6045824 All TT=196 CT=44 CC=6 TT=184 CT=59 CC=2 .102 .482
Female TT=60 CT=6 CC=1 TT=48 CT=16 CC=1 .054 .037
Male TT=136 CT=38 CC=5 TT=135 CT=43 CC=1 .225 .739
PDYN rs6035222 All GG=193 AG=47 AA=7 GG=175 AG=69 AA=2 .02 .254
Female GG=59 AG=6 AA=2 GG=48 AG=18 AA=1 .024 .065
Male GG=134 AG=41 AA=5 GG=126 AG=51 AA=1 .136 .78
PDYN rs6035235 All TT=197 GT=45 GG=5 TT=184 GT=59 GG=2 .165 .405
Female TT=60 GT=6 GG=1 TT=47 GT=17 GG=1 .033 .024
Male TT=137 GT=39 GG=4 TT=136 GT=42 GG=1 .384 .755
PDYN rs12480838 All CC=176 CT=65 TT=6 CC=168 CT=69 TT=5 .842 .751
Female CC=51 CT=16 TT=0 CC=42 CT=22 TT=1 .248 .115
Male CC=125 CT=49 TT=6 CC=125 CT=47 TT=4 .82 .635
PDYN rs2235751 All AA=137 AG=92 GG=14 AA=126 AG=103 GG=14 .582 .409
Female AA=35 AG=28 GG=1 AA=34 AG=30 GG=3 .602 .482
Male AA=102 AG=64 GG=13 AA=91 AG=73 GG=11 .512 .544
PDYN rs3830064 All AA=175 AC=67 CC=5 AA=170 AC=70 CC=7 .79 .543
Female AA=50 AC=17 CC=0 AA=43 AC=22 CC=2 .205 .118
Male AA=125 AC=50 CC=5 AA=126 AC=48 CC=5 .979 .867
PDYN rs7272891 All CC=207 CG=38 GG=2 CC=205 CG=35 GG=4 .677 .867
Female CC=53 CG=14 GG=0 CC=54 CG=12 GG=0 .693 .693
Male CC=154 CG=24 GG=2 CC=150 CG=23 GG=4 .699 .655
PDYN rs10854244 All AA=143 AT=87 TT=17 AA=127 AT=104 TT=15 .275 .323
Female AA=38 AT=26 TT=3 AA=32 AT=31 TT=4 .578 .309
Male AA=105 AT=61 TT=14 AA=94 AT=73 TT=11 .362 .552
aUncorrected p-value of FAMHAP statistic for association between SNPs and alcohol dependence.
bp-value of the Armitage’s trend test.
Significance is indicated in bold.
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Tab. 4.6: PENK and POMC SNPs major allele frequency and association with alcohol dependence
in the Swedish sample.
Gene Marker SNP
Genomic
Sample
Control
Cases pc OR CId
Locationa Subjectsb
PENK rs12545109 C\A 57476460 All .763 .768 .811 1.03 [.807-1.315]
C\A Female .795 .795 1.000 1.004 [.636-1.584]
C\A Male .748 .756 .765 1.045 [.782-1.397]
PENK rs2576581 G\A 57528504 All .536 .522 .599 .946 [.769-1.164]
G\A Female .496 .518 .638 1.092 [.757-1.575]
G\A Male .556 .523 .303 .876 [.680-1.127]
PENK rs12548084 C\T 57540810 All .953 .943 .407 .822 [.517-1.306]
C\T Female .957 .939 .366 .682 [.297-1.569]
C\T Male .950 .944 .675 .887 [.507-1.552]
PENK rs2670029 C\A 57547550 All .580 .571 .735 .964 [.782-1.189]
C\A Female .547 .577 .516 1.131 [.780-1.639]
C\A Male .595 .566 .358 .888 [.688-1.144]
POMC rs2164808 G\A 25230680 All .546 .544 .950 .993 [.806-1.224]
G\A Female .534 .527 .877 .971 [.671-1.406]
G\A Male .551 .550 .975 .995 [.773-1.281]
POMC rs7589318 G\A 25231876 All .708 .674 .168 .854 [.682-1.069]
G\A Female .709 .664 .293 .808 [.543-1.202]
G\A Male .707 .678 .319 .871 [.663-1.144]
POMC rs1866146 T\C 25234077 All .610 .622 .656 1.049 [.849-1.297]
T\C Female .641 .600 .363 .840 [.577-1.223]
T\C Male .596 .632 .251 1.163 [.899-1.505]
POMC rs6713532 T\C 25238337 All .776 .741 .118 .824 [.646-1.051]
T\C Female .795 .732 .114 .704 [.456-1.089]
T\C Male .767 .748 .483 .900 [.671-1.208]
POMC rs934778 T\C 25242728 All .698 .745 .048 1.264 [1.002-1.593]
T\C Female .698 .750 .219 1.296 [.857-1.962]
T\C Male .698 .742 .128 1.242 [.939-1.643]
POMC rs3769671 A\C 25243657 All .963 .963 .944 .980 [.569-1.688]
A\C Female .966 .926 .055 .440 [.186-1.040]
A\C Male .962 .980 .103 1.888 [.869-4.103]
POMC rs6545976 G\T 25248154 All .969 .962 .462 .809 [.459-1.425]
G\T Female .962 .973 .505 1.427 [.499-4.076]
G\T Male .972 .961 .310 .696 [.345-1.405]
POMC rs6719226 C\G 25249516 All .969 .962 .451 .805 [.457-1.417]
C\G Female .962 .973 .516 1.414 [.495-4.040]
C\G Male .972 .961 .304 .694 [.344-1.399]
POMC rs874401 C\T 25255784 All .825 .794 .135 .817 [.627-1.065]
C\T Female .872 .791 .021 .556 [.337-.919]
C\T Male .803 .795 .748 .950 [.694-1.300]
a Genomic location is based on National Center for Biotechnology Information (NCBI) human genome assembly B36.
b The allele frequency is shown for the left allele.
c Uncorrected p-value of FAMHAP statistic for allele frequency differences between cases and controls.
d 95% confidence interval.
Significance is indicated in bold.
To confirm the association results obtained in the German sample, genotyping of a replication
cohort was performed. For this purpose, a Swedish cohort of alcoholics and controls was stud-
ied. Genotype distributions were in HWE, with the exception of two markers (rs2164808 p
= 0.044, rs6045733 p = 0.013), which significantly deviated from HWE in the controls group
(Appendix). These two SNPs did not show significant frequency differences between cases and
controls (Tab. 4.6).
None of the SNPs typed for PENK showed significant frequency differences compar-
ing Swedish cases and controls. Allele and genotype distribution of the POMC marker
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Tab. 4.7: PENK and POMC SNPs genotype distribution and association with alcohol dependence
in the Swedish sample.
Gene Marker Sample Control Subjects Cases
p p
(Global)a (Armitage)b
PENK rs12545109 All CC=211 AC=135 AA=19 CC=205 AC=134 AA=15 .822 .806
Female CC=75 AC=36 AA=6 CC=70 AC=35 AA=5 .969 1.000
Male CC=136 AC=99 AA=13 CC=134 AC=98 AA=10 .845 .757
PENK rs2576581 All GG=104 AG=177 AA=78 GG=91 AG=192 AA=75 .464 .593
Female GG=28 AG=59 AA=29 GG=28 AG=61 AA=24 .792 .629
Male GG=76 AG=118 AA=49 GG=62 AG=130 AA=51 .360 .297
PENK rs12548084 All CC=335 CT=33 TT=1 CC=319 CT=39 TT=1 .686 .407
Female CC=108 CT=8 TT=1 CC=101 CT=12 TT=1 .608 .393
Male CC=227 CT=25 TT=0 CC=216 CT=27 TT=0 .666 .666
PENK rs2670029 All CC=121 AC=180 AA=63 CC=107 AC=189 AA=57 .546 .728
Female CC=36 AC=56 AA=25 CC=34 AC=59 AA=17 .486 .510
Male CC=85 AC=124 AA=38 CC=72 AC=130 AA=40 .544 .341
POMC rs2164808 All GG=98 AG=198 AA=65 GG=101 AG=181 AA=70 .644 .95
Female GG=34 AG=56 AA=26 GG=34 AG=48 AA=28 .767 .882
Male GG=64 AG=142 AA=39 GG=66 AG=133 AA=42 .817 .964
POMC rs7589318 All GG=178 AG=158 AA=27 GG=163 AG=146 AA=41 .151 .169
Female GG=59 AG=48 AA=10 GG=51 AG=44 AA=15 .463 .307
Male GG=119 AG=110 AA=17 GG=111 AG=102 AA=26 .307 .313
POMC rs1866146 All TT=129 CT=184 CC=49 TT=143 CT=163 CC=55 .311 .654
Female TT=49 CT=52 CC=16 TT=42 CT=54 CC=19 .665 .370
Male TT=80 CT=132 CC=33 TT=100 CT=107 CC=36 .084 .243
POMC rs6713532 All TT=220 CT=125 CC=19 TT=190 CT=137 CC=22 .266 .118
Female TT=74 CT=38 CC=5 TT=58 CT=45 CC=7 .266 .111
Male TT=146 CT=87 CC=14 TT=132 CT=92 CC=14 .712 .482
POMC rs934778 All TT=171 CT=169 CC=26 TT=189 CT=145 CC=17 .116 .038
Female TT=57 CT=48 CC=11 TT=61 CT=43 CC=6 .423 .218
Male TT=114 CT=121 CC=15 TT=127 CT=102 CC=11 .255 .104
POMC rs3769671 All AA=341 AC=27 CC=0 AA=335 AC=25 CC=1 .588 .944
Female AA=110 AC=8 CC=0 AA=99 AC=15 CC=1 .160 .059
Male AA=231 AC=19 CC=0 AA=234 AC=10 CC=0 .098 .098
POMC rs6545976 All GG=348 GT=21 TT=1 GG=328 GT=25 TT=1 .746 .473
Female GG=109 GT=7 TT=1 GG=104 GT=6 TT=0 .613 .526
Male GG=239 GT=14 TT=0 GG=223 GT=19 TT=0 .301 .301
POMC rs6719226 All CC=350 CG=21 GG=1 CC=328 CG=25 GG=1 .735 .461
Female CC=110 CG=7 GG=1 CC=104 CG=6 GG=0 .617 .536
Male CC=240 CG=14 GG=0 CC=223 CG=19 GG=0 .296 .296
POMC rs874401 All CC=249 CT=101 TT=13 CC=220 CT=119 TT=13 .213 .135
Female CC=89 CT=26 TT=2 CC=69 CT=36 TT=5 .074 .022
Male CC=160 CT=75 TT=11 CC=150 CT=83 TT=8 .563 .747
aUncorrected p-value of FAMHAP statistic for association between SNPs and alcohol dependence.
bp-value of the Armitage’s trend test.
Significance is indicated in bold.
rs934778 differed significantly among alcoholics and healthy controls in the whole sample.
For rs3769671 and rs874401 the association was only detected in the female subgroup (Tab .4.6
and Tab. 4.7).
In case of the PDYN locus, rs6112177, rs2235749, rs2235751 and rs10854244 unadjusted
p values for allele as well as genotype distributions were identified as significant examining the
whole sample. For three of them (rs2235749, rs2235751, rs10854244) the same was seen in the
male subgroup.
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Tab. 4.8: PDYN SNPs major allele frequency and association with alcohol dependence in the
Swedish sample.
Gene Marker SNP
Genomic
Sample
Control
Cases pc OR CId
Locationa Subjectsb
PDYN rs6112177 C\A 1897127 All .795 .848 .009 1.432 [1.092-1.878]
C\A Female .791 .86 .051 1.622 [.995-2.645]
C\A Male .798 .842 .069 1.355 [.976-1.880]
PDYN rs6045733 G\A 1898858 All .887 .911 .127 1.307 [.926-1.847]
G\A Female .876 .904 .347 1.325 [.737-2.382]
G\A Male .892 .916 .214 1.313 [.854-2.018]
PDYN rs6045761 A\G 1901363 All .895 .908 .406 1.158 [.819-1.638]
A\G Female .876 .905 .333 1.341 [.740-2.429]
A\G Male .903 .909 .765 1.067 [.696-1.637]
PDYN rs6045784 T\C 1904663 All .889 .905 .338 1.181 [.840-1.661]
T\C Female .869 .891 .466 1.235 [.700-2.179]
T\C Male .899 .910 .536 1.144 [.747-1.753]
PDYN rs2235749 G\A 1907939 All .616 .700 .001 1.454 [1.169-1.81]
G\A Female .616 .696 .073 1.423 [.967-2.093]
G\A Male .616 .701 .005 1.458 [1.118-1.902]
PDYN rs910080 A\G 1908226 All .891 .910 .226 1.238 [.876-1.749]
A\G Female .874 .904 .298 1.364 [.758-2.454]
A\G Male .900 .914 .427 1.190 [.774-1.831]
PDYN rs10485703 A\G 1908313 All .723 .762 .091 1.227 [.968-1.554]
A\G Female .712 .743 .456 1.170 [.774-1.768]
A\G Male .727 .769 .131 1.250 [.936-1.670]
PDYN rs6045819 A\G 1909134 All .729 .771 .068 1.249 [.984-1.587]
A\G Female .728 .752 .556 1.134 [.746-1.722]
A\G Male .730 .779 .074 1.305 [.974-1.748]
PDYN rs6045824 T\C 1909977 All .891 .910 .226 1.238 [.876-1.749]
T\C Female .874 .904 .298 1.364 [.758-2.454]
T\C Male .900 .914 .427 1.190 [.774-1.831]
PDYN rs6035222 G\A 1911413 All .886 .903 .274 1.206 [.862-1.688]
G\A Female .870 .900 .307 1.350 [.758-2.404]
G\A Male .893 .906 .511 1.150 [.758-1.743]
PDYN rs6035235 T\G 1915155 All .883 .893 .533 1.110 [.799-1.541]
T\G Female .868 .883 .645 1.139 [.654-1.986]
T\G Male .890 .899 .634 1.105 [.734-1.662]
PDYN rs12480838 C\T 1917824 All .851 .880 .108 1.281 [.947-1.734]
C\T Female .855 .874 .56 1.173 [.686-2.005]
C\T Male .849 .881 .141 1.316 [.912-1.900]
PDYN rs2235751 A\G 1917934 All .726 .780 .02 1.333 [1.045-1.701]
A\G Female .745 .784 .342 1.238 [.797-1.923]
A\G Male .718 .775 .041 1.356 [1.012-1.816]
PDYN rs3830064 A\C 1923679 All .827 .855 .151 1.231 [.927-1.634]
A\C Female .827 .835 .834 1.054 [.646-1.720]
A\C Male .827 .863 .125 1.312 [.927-1.858]
PDYN rs7272891 C\G 1924818 All .907 .924 .239 1.249 [.862-1.811]
C\G Female .905 .948 .079 1.903 [.919-3.943]
C\G Male .908 .914 .728 1.081 [.697-1.675]
PDYN rs10854244 A\T 1925045 All .713 .759 .05 1.266 [1.00-1.602]
A\T Female .726 .743 .666 1.096 [.723-1.661]
A\T Male .707 .765 .041 1.348 [1.012-1.796]
a Genomic location is based on National Center for Biotechnology Information (NCBI) human genome assembly B36.
b The allele frequency is shown for the left allele.
c Uncorrected p-value of FAMHAP statistic for allele frequency differences between cases and controls.
d 95% confidence interval.
Significance is indicated in bold.
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Tab. 4.9: PDYN SNPs genotype distribution and association with alcohol dependence in the
Swedish sample.
Gene Marker Sample Control Subjects Cases
p p
(Global)a (Armitage)b
PDYN rs6112177 All CC=232 AC=115 AA=17 CC=260 AC=92 AA=9 .037 .01
Female CC=75 AC=35 AA=7 CC=85 AC=26 AA=3 .172 .061
Male CC=157 AC=80 AA=10 CC=173 AC=65 AA=6 .191 .069
PDYN rs6045733 All AA=281 AG=73 GG=4 AA=299 AG=58 GG=3 .299 .126
Female AA=91 AG=23 GG=3 AA=93 AG=20 GG=1 .551 .359
Male AA=190 AG=50 GG=1 AA=204 AG=37 GG=2 .251 .206
PDYN rs6045761 All TT=296 CT=70 CC=4 TT=290 CT=59 CC=3 .707 .405
Female TT=91 CT=23 CC=3 TT=90 CT=19 CC=1 .557 .346
Male TT=205 CT=47 CC=1 TT=199 CT=40 CC=2 .706 .762
PDYN rs6045784 All TT=292 GT=74 GG=4 TT=289 GT=57 GG=5 .4 .343
Female TT=90 GT=25 GG=3 TT=88 GT=20 GG=2 .78 .48
Male TT=202 GT=49 GG=1 TT=200 GT=37 GG=3 .302 .533
PDYN rs2235749 All GG=126 AG=193 AA=42 GG=176 AG=155 AA=31 .001 .0005
Female GG=45 AG=53 AA=18 GG=54 AG=52 AA=9 .148 .072
Male GG=81 AG=140 AA=24 GG=120 AG=102 AA=22 .001 .003
PDYN rs910080 All TT=289 CT=71 CC=4 TT=301 CT=59 CC=3 .474 .225
Female TT=89 CT=23 CC=3 TT=94 CT=20 CC=1 .51 .311
Male TT=200 CT=48 CC=1 TT=205 CT=38 CC=2 .466 .42
PDYN rs10485703 All GG=182 AG=152 AA=23 GG=208 AG=137 AA=18 .215 .083
Female GG=61 AG=39 AA=13 GG=62 AG=47 AA=6 .191 .466
Male GG=121 AG=113 AA=10 GG=144 AG=89 AA=12 .081 .112
PDYN rs6045819 All AA=187 AG=148 GG=23 AA=213 AG=132 GG=17 .175 .063
Female AA=65 AG=36 GG=13 AA=64 AG=45 GG=6 .167 .572
Male AA=122 AG=112 GG=10 AA=147 AG=86 GG=11 .055 .061
PDYN rs6045824 All AA=289 AG=71 GG=4 AA=301 AG=59 GG=3 .474 .225
Female AA=89 AG=23 GG=3 AA=94 AG=20 GG=1 .51 .311
Male AA=200 AG=48 GG=1 AA=205 AG=38 GG=2 .466 .42
PDYN rs6035222 All AA=284 AG=75 GG=4 AA=295 AG=64 GG=3 .543 .271
Female AA=88 AG=24 GG=3 AA=93 AG=21 GG=1 .512 .316
Male AA=196 AG=51 GG=1 AA=200 AG=42 GG=2 .546 .502
PDYN rs6035235 All GG=277 AG=80 AA=2 GG=287 AG=71 AA=3 .635 .521
Female GG=86 AG=26 AA=2 GG=90 AG=23 AA=2 .874 .648
Male GG=191 AG=54 AA=0 GG=195 AG=47 AA=1 .468 .616
PDYN rs12480838 All CC=263 CT=95 TT=7 CC=278 CT=79 TT=4 .261 .103
Female CC=85 CT=25 TT=4 CC=88 CT=25 TT=2 .7 .572
Male CC=178 CT=70 TT=3 CC=187 CT=54 TT=2 .308 .127
PDYN rs2235751 All AA=180 AG=150 GG=21 AA=214 AG=121 GG=17 .04 .018
Female AA=61 AG=42 GG=7 AA=67 AG=40 GG=4 .564 .335
Male AA=119 AG=108 GG=14 AA=144 AG=81 GG=13 .044 .037
PDYN rs3830064 All AA=244 AC=106 CC=9 AA=267 AC=85 CC=10 .184 .152
Female AA=79 AC=29 CC=5 AA=83 AC=26 CC=6 .845 .845
Male AA=165 AC=77 CC=4 AA=181 AC=59 CC=4 .211 .114
PDYN rs7272891 All CC=303 CG=58 GG=5 CC=309 CG=53 GG=1 .23 .243
Female CC=95 CG=20 GG=1 CC=104 CG=10 GG=1 .154 .086
Male CC=208 CG=38 GG=4 CC=203 CG=42 GG=0 .122 .729
PDYN rs10854244 All AA=176 AT=153 TT=25 AA=211 AT=129 TT=23 .075 .048
Female AA=59 AT=46 TT=8 AA=66 AT=39 TT=10 .556 .673
Male AA=117 AT=107 TT=17 AA=143 AT=89 TT=13 .093 .037
aUncorrected p-value of FAMHAP statistic for association between SNPs and alcohol dependence.
bp-value of the Armitage’s trend test.
Significance is indicated in bold.
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4.2.3 Haplotype analysis
Haplotype analysis provides a valuable tool to access information about marker combinations.
A haplotype also provides information of all not-analyzed SNPs in LD with markers of this
haplotype. Combinations of neighboring markers were successively analyzed. No PENK or
PDYN haplotypes with significant frequency differences between cases and controls in both
cohorts were found. Interestingly, for POMC an association with the T-A haplotype of mark-
ers rs934778 and rs3769671 in the group of alcohol-dependent women in the German and the
Swedish sample was detected. To further substantiate these results the number of German fe-
males was increased by genotyping additional cases and controls for the two markers. Including
them into haplotype analysis additionally confirmed the association (German females p = 0.012,
Swedish females p = 0.016) (Tab. 4.10).
Tab. 4.10: Haplotype frequencies and association of POMC with alcohol dependence in the
German and Swedish sample.
Sample Marker German Swedish
rs934778 rs3769671 Control Subjects Cases p Control Subjects Cases p
All C A .28 .25 .27 .26 .21 .077
T A .69 .73 .70 .74
C C .03 .02 .04 .04
Females C A .28 .19 .012 .27 .18 .016
T A .69 .78 .69 .75
C C .02 .02 .03 .07
Male C A .27 .29 .26 .27 .24 .12
T A .69 .68 .69 .74
C C .04 .02 .04 .02
Significance is indicated in bold.
Chapter 5
Discussion
Within the scope of this thesis the generation of a new mouse model was reported. In this
mouse strain, Penk1loxe/loxe, the coding region of the murine preproenkephalin gene is flanked
by two loxP sites and lacZ is introduced as a reporter gene. The introduction of loxP sites al-
lows the region- or cell-specific knockout of enkephalin and the lacZ gene is expressed after cre
recombinase-mediated deletion of the enkephalin coding exons. In this context, a second con-
stitutive enkephalin knockout strain denoted as Penk1loxd/loxd expressing lacZ under the con-
trol of the endogenous enkephalin promoter was established. Additionally, the virus-mediated
knockout in Penk1loxe/loxe mice was analyzed and initial experiments were conducted. These
data will be discussed in the first two sections of this chapter, whereas the results obtained
for PENK, POMC and PDYN in the human case-control samples will be discussed in the last
section.
5.1 Generation and validation of the new mouse model
One aim of this thesis was the generation of a mouse line with a floxed preproenkephalin locus.
The cre/lox technology enables the analysis of gene functions in specific tissues or cell types,
or during specific stages of a disease process.
A targeting construct was electroporated into ES cells to mutate the murine Penk1 locus.
Homologous recombination of the target construct was observed in the expected frequencies in
relation to the generation of constitutive Penk−/− mice (Prof. A. Zimmer, personal communi-
cation). The frequency was also in line with commonly reported homologous recombination
frequencies of 1–3% (CAPECCHI, 1989). An exponential relationship between the length of
the homologous region and the targeting frequency was described, with an increase in ho-
mology leading to higher recombination frequencies (CAPECCHI, 1989). Since the 5’ loxP
site introduced in the Penk1 gene locus was located at the margin of the homology region, its
integration into the mutant gene locus was uncertain. This loxP site was located around 5 kb
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upstream of the neo gene that was introduced as selectable marker. The frequency of cocon-
version decreases with the distance of two genetic regions (AHN AND LIVINGSTON, 1986). A
study on mitotic gene conversion length in yeast indicated coconversion rates of less than 25%
between two markers more than 1 kb apart (AHN AND LIVINGSTON, 1986). Nevertheless,
one clone showed full length recombination. This ES cell clone containig the mutated Penk1
gene was successfully injected in blastocysts, leading to chimeric animals that transmitted the
mutation to progeny.
The mutated gene locus consisted of a neo gene, a lacZ gene as reporter and three loxP sites
flanking the Penk1 coding exons and the neo gene. In these mice multiple recombination events
can take place. To remove one 3’ loxP site and to excise the neo gene, these mice were mated to
mouse strains expressing cre recombinase during embryonic development. The frequency and
extent of the excision depends on the length of the floxed sequence. Shorter sequences led to
higher excision frequencies (LAKSO ET AL., 1996). Because of their proximity, recombination
between the loxP sites flanking the neo gene should be favored. Mating of mice, expressing cre
recombinase under the Pgk-1 promoter, to the floxed Penk1 mice always led to deletion of the
entire floxed region. The successful deletion of the coding exons and the neo gene proved
the functionality of the loxP sites. Recombination either occurred directly between the 1st
and the 3rd loxP site or sequential recombination events took place due to ongoing or strong
cre recombinase activity. It is likely that sequential recombination events took place because
recombination between adjacent loxP sites is favored (LAKSO ET AL., 1996). In the Pgk-cre
strain, cre recombinase expression is under dominant maternal control, as cre recombinase was
already active in the early diploid phase of oogenesis (LALLEMAND ET AL., 1998). Therefore,
recombination can take place as early as the pronuclear fusion. This possibly explains the high
efficiency of excision observed in matings with floxed Penk1 mice.
In EIIa-cre animals, cre expression is under the control of the adenoviral EIIa promoter.
This promoter confines the expression of cre recombinase to a very early state of embryogen-
esis, most likely to the one-cell embryo (DOOLEY ET AL., 1989). However, it was reported
that in these mice cre recombinase expression could occur past the zygote stage, resulting in
mosaicism due to incomplete recombination (LAKSO ET AL., 1996). Indeed, in contrast to
matings of Penk1lox/wt x Pgk-cre animals, offspring of Penk1lox/wt mice and EIIa-cre mice
showed to some extend a mosaic pattern of different alleles. Hence the loxe allele was present as
well, demonstrating successful excision of the neo gene. Further mating of these offspring fixed
the genetic alterations and enabled the generation of the two new mouse lines, Penk1loxe/loxe
and Penk1loxd/loxd.
Mutation of the Penk1 gene locus led to decreased preproenkephalin expression. In Penk1lox/lox
mice mRNA levels were reduced compared to wild type littermates. It was reported that genetic
modification, for example introduction of a neo gene, can influence gene expression of nearby
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genes (VALERA ET AL., 1994; HLAVATY ET AL., 2004). In vitro, introduction of a neo gene
altered expression of endogenous genes (VALERA ET AL., 1994) and led to decreased expres-
sion of a eGFP transgene (HLAVATY ET AL., 2004). However, reduced mRNA levels were also
observed in mice homozygous for the loxe allele in which the neo gene is not present. As this
reduction had the same magnitude in Penk1lox/lox and Penk1loxe/loxe a specific influence of the
neo gene on preproenkephalin expression could be excluded.
Another possible reason for reduced mRNA levels might be the location of the first loxP site.
In transcript ENSMUST00000070375, this loxP site is located in the 5’UTR. It is known that
the UTRs can influence mRNA stability or expression (WANG ET AL., 2006; KEYSER ET AL.,
2009). The analysis of transcript-specific expression levels revealed that both transcripts had
lower expression levels in Penk1loxe/loxe mice and the magnitude of reduction was similar for
ENSMUST00000070375 and ENSMUST00000108381. This indicates that the location of the
first loxP site in the 5’ UTR of ENSMUST00000070375 did not lead to a selective down-
regulation of this transcript. The detected difference in expression levels was more pronounced
using TaqMan® assays. That was probably due to their higher specificity compared to SYBR
green detection (TIAN ET AL., 2004; HEIN ET AL., 2001). The analysis of Penk1loxd/loxd
mice proved the absence of both Penk1 transcripts after cre recombinase-mediated knockout.
A further reason for the reduced mRNA level could be an influence of the lacZ reporter
gene on mRNA expression. In the targeted gene locus, the splice acceptor site and the ATG of
the Penk1 gene were fused in frame to the lacZ coding sequence. This enables lacZ expression
under the control of the enkephalin promoter after excision of the Penk1 coding exons 2 and 3.
It is very unlikely that the lacZ sequence was already transcribed in homozygous lox or loxe
mice as the stop codon of Penk1 should terminate transcription before. Indeed, ß-galactosidase
activity was only detected in Penk1loxd/loxd mice, suggesting that the lacZ gene is only tran-
scribed subsequent to the knockout of enkephalin. Therefore, the presence of the lacZ transcript
and alternative splicing of Penk1 exon 2 and 3 did not account for the reduced mRNA level in
Penk1lox/lox and Penk1loxe/loxe mice.
However the introduction of the lacZ and the neo gene modified the 3’ flanking of the
Penk1 gene locus. Different studies reported that 3’ flanking regions of genes are involved in
transcriptional regulation (ZARUDNAYA ET AL., 2003; CHEN ET AL., 2006). Modification
of the 3’ region can for example influence the binding of cis-acting transcriptional enhancers
or repressors (CHEN ET AL., 2006). Therefore the most probable explanation for the reduced
preproenkephalin mRNA level is that the 3’ introduction of the lacZ and the neo sequence
impair the binding of a transcriptional enhancer.
It was proposed that Leu-enkephalin can be generated from preprodynorphin via a different
cleavage pathway (DAY ET AL., 1998; ZAMIR ET AL., 1984). The results reported herein
revealed that reduction or absence of preproenkephalin mRNA did not lead to a compen-
satory up-regulation of preprodynorphin expression, though the presence of Leu-enkephalin
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in Penk1loxd/loxd mice supports the suggestion made by Day and co-workers. However, Leu-
enkephalin anti-sera often show a cross-reactivity to Dynorphin A (GARZÓN AND PICKEL,
2004; MILNER ET AL., 1989). The anti-serum used in this work exhibits a cross-reactivity of
29 % to dynorphin A (according to specification provided by the supplier). Therefore, arround
one third of the detected peptide might be dynorphin A and not Leu-enkephalin. Since the pep-
tide level detected in Penk1loxd/loxd mice represent 37 % of the amount observed in Penk1wt/wt
mice, one could speculate that most of it was dynorphin A.
Altogether the peptide levels are in line with the expression data. A reduction of Met- and
Leu-enkephalin was observed in mice homozygous for the loxe allele, Met-enkephalin was
absent in null allele mice, whereas Leu-enkephalin was further reduced in these knockout mice.
The higher amount of Met-enkephalin compared to Leu-enkephalin is attributed to the fact that
preproenkephalin can give rise to four copies of Met- and only one copy of Leu-enkephalin
(WEISINGER, 1995; ZAMIR ET AL., 1984).
Penk1−/− mice are commonly used as a genetic model for enhanced anxiety responses. In this
mouse strain, an anxiogenic phenotype was observed in the zero maze test, independent of ge-
netic background and animal facility (BILKEI-GORZÓ ET AL., 2008; BILKEI-GORZO ET AL.,
2004; KÖNIG ET AL., 1996). The zero maze paradigm was therefore chosen to evaluate
whether the reduced enkephalin level in Penk1loxe/loxe mice resulted in phenotypic differences.
For two of the parameters measured, namely distance traveled and time spent in the open area,
no significant genotype effect was observed. Reduced values for these two parameters are the
most obvious signs of an anxiogenic phenotype. Additionally, a significant higher latency to en-
ter the closed area of the maze was connected to an increased anxiety (BILKEI-GORZÓ ET AL.,
2008; BILKEI-GORZO ET AL., 2004). Hence, the reduced expression levels of Penk1loxe/loxe
compared to Penk1wt/wt mice resulted in slightly higher anxiety levels in Penk1loxe/loxe mice,
indicated by the higher latency to enter the closed area of the maze. However, compared to
constitutive Penk1 knockout mice (BILKEI-GORZÓ ET AL., 2008; BILKEI-GORZO ET AL.,
2004; KÖNIG ET AL., 1996), the anxiety phenotype observed in Penk1loxe/loxe is very weak.
The Penk1loxe/loxe mice provide a valuable tool to further clarify the role of enkephalin in
addiction related-behaviors. Enkephalins are widely expressed in brain structures involved in
reward and reinforcement. Additionally, constitutive Penk1 knockout mice were shown to in-
fluence drug-related behaviors for many drugs of abuse (VALVERDE ET AL., 2000; BERREN-
DERO ET AL., 2005; RACZ ET AL., 2008). For example nicotine was not rewarding in
Penk1−/− mice (BERRENDERO ET AL., 2005). Another example is the reduction of ∆9-
tetrahydrocannabinol (THC) withdrawal symptoms in enkephalin-deficient mice (VALVERDE
ET AL., 2000). The subpopulations of enkephalinergic neurons modulating these processes are
so far unclear (BERRENDERO ET AL., 2005).
The analysis of conditional knockout mice can provide new insights. One example is the
CB1 receptor that mediates most of the cannabinoid effects in the CNS (VALVERDE ET AL.,
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2000; MONORY ET AL., 2007). These receptors are highly expressed on GABAergic neu-
rons and this CB1 subpopulation was believed to mediate most of the effects of exogenously
administered and endogenously released cannabinoids (FREUND ET AL., 2003). Instead, the
analysis of conditional CB1 knockout mice revealed that CB1 signaling on glutamatergic, but
not on GABAergic neurons, accounts primarily for the behavioral effects induced by high doses
of THC (MONORY ET AL., 2007). Analysis of the newly generated Penk1loxe/loxe mice will
help to elucidate the role of enkephalin in processes relevant for drug addiction.
5.2 Region-specific knockout of enkephalin
The newly generated Penk1loxe/loxe mouse line provides the possibility to study the effect of
region- or cell-specific knockout of preproenkephalin. Thus, it was crucial to establish tech-
niques that allow the detection of such knockouts. The tissue distribution of enkephalin was
assessed by in situ hybridization. The pronounced expression of preproenkephalin in the stria-
tum was completely in line with expression data published before (YOSHIKAWA ET AL., 1984;
WEISINGER ET AL., 1992; BRANCH ET AL., 1992; WEISINGER, 1995). After knockout of
the Penk1 coding exons the signal was absent. This results confirmed that in situ hybridization
can be used for the analysis of virus-mediated knockout.
Alternatively, the lacZ gene was introduced into the Penk1 gene locus to function as a
reporter gene. By this, X-gal staining on brain sections demonstrating ß-galactosidase ac-
tivity provides another tool to prove the absence of enkephalin. In Penk1loxd/loxd mice, ß-
galactosidase activity was detected in regions of former enkephalin expression (ZAMIR ET AL.,
1984; GARZÓN AND PICKEL, 2004), demonstrating the functionality of the lacZ reporter
gene. One limitation of this method was the lower sensitivity compared to in situ hybridization,
as it is based on protein activity instead of directly assessing gene expression.
Since the applied viruses express either eGFP or cre recombinase tagged with eGFP, another
analysis method was the detection of GFP by immunohistochemistry. In the present study, this
technique was used to detect the tissue distribution of the virus.
Injection of cre recombinase expressing viruses resulted in a knockout of enkephalin at the
injection site, whereas injection of the eGFP expressing virus did not effect preproenkephalin
mRNA expression. This demonstrated the efficacy of the virus-mediated knockout in floxed
Penk1 animals. Targeting of the NAc led to GFP expression in the accumbens core and shell
region. However, the viral expression was not detected in all parts of the NAc. Instead, the
observed transduction for AAV2 was always essentially restricted to the injection site. The
distribution of AAV2 observed in these experiments was in line with previous studies, also
showing restricted transduction of AAV2 viruses (BURGER ET AL., 2005; TAYMANS ET AL.,
2007; HOWARD ET AL., 2008). If AAV2-Cre viruses do not transduce all parts of the NAc,
preproenkephalin expression is not completely abolished in the NAc. One option to reach virus
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transduction in the whole NAc would be the use of other AAV serotypes. It is known that
other serotype capsids could increase the virus distribution. For two other human derived AAV
serotype capsids (1 and 5) and for the non-human primate derived AAV7 capsid efficient trans-
duction in the adult mouse brain was described (TAYMANS ET AL., 2007). On the other hand,
they often exhibited retrograde transduction in untargeted areas of the CNS and showed a dif-
ferent tropism including increased transduction of glia cells and oligodendrocytes (TAYMANS
ET AL., 2007; BURGER ET AL., 2005). The advantage of AAV2 viruses is that retrograde
transduction was not observed and its expression was primarily neuronal (TAYMANS ET AL.,
2007; BURGER ET AL., 2005; HOWARD ET AL., 2008). This has to be considered when
using alternative serotypes. Another study using higher concentrated AAV2 solutions achieved
virus-mediated knockout in the hippocampus, a much larger brain region (MONORY ET AL.,
2006). Therefore the best option would be to use higher concentrated AAV2s to increase the
virus distribution.
Dopamine release in the NAc is essential for the rewarding properties of most addictive drugs
(FELTENSTEIN AND SEE, 2008; NESTLER, 2004A; SPANAGEL ET AL., 1992). To evaluate
the influence of enkephalin on nicotine-induced dopamine release, nicotine-related behaviors
were studied in the newly generated floxed preproenkephalin mice. In a preliminary experi-
ment, injections of either cre recombinase (CRE) or GFP (GFP) expressing viruses into the
NAc were performed. Subsequently, these mice underwent the nicotine self-administration
paradigm. This experiment revealed no difference between either CRE- or GFP-injected an-
imals. Both experimental groups learned to self-administer nicotine solution indicating that
nicotine was rewarding for both groups. In contrast, it was shown before that Penk1−/− mice
did not exhibit nicotine-induced place preference, and the nicotine-dependent increase in ex-
tracellular dopamine levels in the NAc was attenuated (BERRENDERO ET AL., 2005). These
results in Penk1−/− demonstrated that enkephalin contributes to the rewarding properties of
nicotine. It is unclear, which neurons meditate the enkephalinergic modulation of dopamine re-
lease. Enkephalinergic interneurons as well as enkephalinergic inputs from the NAc are present
in the VTA (GARZÓN AND PICKEL, 2004). In a different study, nicotine administration in-
duced the release of enkephalin in the NAc (HOUDI ET AL., 1991). Thus, the role of enkephalin
in the NAc and the VTA needed further investigation. The results observed in the Penk1loxe/loxe
animals do not suggest a role for preproenkephalin expressed in NAc cell bodies in mediating
nicotine reinforcement. In this experiment only 15 of 37 virus-injected mice underwent the
self-administration procedure. Interpretation of these results remains speculative, as the brains
of these mice need to be checked for the virus transduction. In addition, the final number
of animals was small for such behavioral experiments. The small animal number is due to a
high mortality of the mice during catheter implantation for the self-administration experiments.
However, the moderate variance observed during the experiments indicate that results would
not substantially change with increased animal numbers. Still, a role of enkephalin from NAc
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afferents in dopamine release cannot be excluded. Furthermore, as discussed above the virus
probably did not spread in the NAc, indicating that to some extent enkephalin was still present
in some NAc neurons. Further experiments, including viral-mediated knockout of enkephalin
in the VTA, are needed to clarify the role of enkephalinergic neurons on dopamine release in
the NAc.
5.3 Association of opioid peptide genes with alcoholism
The contribution of variants in genes coding for the three endogenous opioid precursor proteins
to alcohol addiction in humans was systematically evaluated in a case-control study. Data ob-
tained in an exploratory genotyping did not point towards an association of these genes with
alcoholism. This is probably due to the small number of cases in this initial group, as the power
to detect genetic association for complex phenotypes largely depends on sample size (COL-
HOUN ET AL., 2003; HOEFGEN ET AL., 2005; MAXWELL ET AL., 2008). The integration of
linkage data into marker selection and data analysis augments the coverage of genetic variation
for a gene locus of interest (SCHAID, 2004; MENG ET AL., 2003). The extended sample size
and the marker selection based on LD data for the detailed genotyping therefore increased the
power to detect genetic association.
5.3.1 Contribution of PENK variants
The LD observed for the German control group and the predicted haplotype structure for the
PENK SNPs indicated high linkage and the presence of one haplotype block. This is in line
with the data provided by the HapMap project for a Caucasian reference population, as high
LD and location in one Haplotype block was predicted for SNPs in the PENK gene locus. The
allele frequencies detected in the present study were similar in the German and the Swedish
sample and in line with the minor allele frequencies (MAFs) indicated in the HapMap database.
The analysis of PENK SNPs did not provide evidence for an association with alcoholism.
For rs12545109, the elevated MAF in German cases was not significant after correction for
multiple testing and was also not replicated in the Swedish sample. The significant frequency
difference detected for rs2576581 in females was due to a reduced allele frequency in the female
control group. Thus, this seemed to be a false positive signal, since for the general population
no frequency differences between males and females were reported for this marker and these
findings were not replicated in Swedish females. In line with the results presented here, an
analysis of a different set of PENK variants in the COGA cohort did not indicate an association
with alcohol dependence. Another study analyzed a CA repeat in the PENK promoter region
and reported negative findings (CHAN ET AL., 1994). Different studies on Penk1 knockout
animals also support the results, as no significant differences in ethanol consumption or ethanol
induced place-preference was observed (RACZ ET AL., 2008; KOENIG AND OLIVE, 2002).
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Together with the observed increase in ethanol consumption in Penk1−/− mice after stress ex-
posure (RACZ ET AL., 2008), these data and the results reported herein implicate a role of
enkephalin in mediating stress relief rather than a general contribution to alcohol consumption.
5.3.2 Contribution of PDYN variants
LD and the haplotype block structure were calculated on the basis of the German control popu-
lation. Both, LD and haplotype structure, resembled those predicted for the PDYN locus accord-
ing to HapMap project data for a Caucasian reference population. However, the contribution of
variants in the PDYN locus remained somewhat unclear.
In the German subgroup, allele frequencies differed significantly among female cases and
controls for several SNPs (rs910080, rs6045819, rs6045824, rs6035235). These markers also
showed significant differences in genotype distributions. Another three markers (rs6045733,
rs2235749, rs6035222) differed significantly in their genotype distributions between female
cases and controls. For these SNPs the significant p-values resulted from an increase in the
number of heterozygous cases. This is reflected by a non significant Armitage p-value for
rs6045733 and rs6035222, indicating the absence of a linear trend among the three genotypes.
Therefore these results seemed to be false positive. Additionally, none of the p-values remained
significant after correction for multiple testing.
The association results observed in the Swedish sample did not overlap with results ob-
served in the German sample. In the Swedish sample four markers differed significantly be-
tween cases and controls (rs6112177, rs2235749, rs2235751, rs10854244). Only for rs2235749
significant differences for allele and genotype distribution were also observed in the German
cohort. In contrast to the results of the German sample, the G allele instead of the A allele
was more frequent in Swedish cases, and the effect was seen in the males subgroup. In general
the association results in the Swedish sample were observed in the whole sample as well as in
the male subgroup, which also contradicts the effects mostly seen in the German female group.
Thus, the absence of overlapping results in these two cohorts indicates that the PDYN variants
analyzed did not contribute to an increased risk to become alcohol-dependent.
In contrast, Xuei and co-workers reported association of PDYN variants with alcoholism
(XUEI ET AL., 2006). In this study nine markers showed significant association with al-
coholism. The SNPs analyzed overlap with the markers studied in the scope of this thesis
(rs6045784, rs2235749, rs910080, rs10485703, rs6045819, rs6035222, rs2235751, rs3830064).
Comparing the association results with the findings of Xuei et al., the role of PDYN variants
remained ambiguous. They found significant p-values for marker rs2235749 that differed signif-
icantly in Swedish males, the whole Swedish sample and in German females. For another three
of their associated SNPs significant p-values were observed in the German cohort (rs910080,
rs6045819, rs6035222). In contrast, rs2235751 associated in the Swedish cohort were not as-
sociated in the Xuei cohort. However, the family-sample used by Xuei et al. showed high
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comorbidity with other drug dependencies and gender influences were not considered (XUEI
ET AL., 2006; REICH ET AL., 1998). Therefore, the studies cannot be compared one-to-one,
which might be the reason for the inconsistent results. A recent study reports association of
one PDYN 3’ UTR haplotype comprised of three SNPs (rs910080, rs910079, rs2235749) in
a Caucasian sample for cocaine dependence and a combined sample for cocaine and alcohol
dependence. The risk haplotype was also associated with lower PDYN mRNA levels in post-
mortem brains in the same study (YUFEROV ET AL., 2009). This indicates that variants in
the 3’ UTR of the PDYN locus could influence preprodynorphin expression. As the association
results of Yuferov et al. and Xuei et al. were obtained in samples showing high comorbidity
with other substance dependencies, PDYN seems to contribute to addiction in general rather
than to alcohol dependence alone. The results of a quantitative trait loci (QTL) analysis using
recombinant QTL ingression strains indicated linkage close to the gene coding for the κ-opioid
receptor, and different studies showed evidence for association of the OPRK gene in humans
(VADASZ ET AL., 2000; XUEI ET AL., 2006; ZHANG ET AL., 2008), indicating a κ-opioid
receptor mediated contribution to an increased risk to develop alcohol dependence. The role of
the gene coding for its endogenous ligand dynorphin remains to be clarified in further studies.
5.3.3 Contribution of POMC variants
For the analyzed genomic region located around the POMC locus the overall LD in the German
control group was weak, resembling the data provided by the HapMap Project for a Caucasian
reference population. The allele frequencies detected in the present study were similar in the
German and the Swedish sample and were also in line with the MAFs indicated in the HapMap
database.
Allele frequencies and genotype distributions of POMC variants differed significantly be-
tween German alcoholics and controls in the female subgroup for rs2164808 and rs934778.
The latter SNP remained significant after Bonferroni correction for multiple testing and sig-
nificant association was also observed in the Swedish sample. In the Swedish group the higher
frequency of the T allele in cases was not gender-specific. Marker rs874401 significantly associ-
ated in Swedish females did not show association in the German cohort. Generally, throughout
both samples, significant p-values were mostly observed in the female subgroup, indicating a
gender-specific contribution of this gene locus. Subsequent haplotype analysis then revealed
that the T-A haplotype of rs934778 and rs3769671 was significantly more frequent among fe-
male cases in both cohorts, verifying the association of the POMC gene locus with alcoholism
in females.
Two other groups studied the contribution of POMC variants to alcoholism, although the
SNPs partly differed between the studies and also from SNPs reported herein (XUEI ET AL.,
2007; ZHANG ET AL., 2009). Only rs6713532 was analyzed throughout all studies and con-
stantly showed no association. Xuei and co-workers also analyzed rs934778, but did not find
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a significant association with alcohol dependence. Nevertheless, this SNP showed a significant
association with a more severe subtype of alcoholism, which was characterized by comorbidity
with opioid dependence (XUEI ET AL., 2007), supporting the association observed in the Ger-
man females and the Swedish sample. The five polymorphisms studied in four different sam-
ples by Zhang and co-workers overlap with SNPs analyzed in this work (rs1866146, rs6713532,
rs3769671, rs6545976, rs6719226), however, rs934778 was not included. In their samples, al-
coholics also showed comorbidity with either cocaine or opioid dependence. For none of the
markers, association with alcohol dependence in an African-American family sample, in an
European-American family sample, or in an African-American case-control sample was found.
However, in an European-American case-control sample significant association of rs6713532
and rs1866146 with alcohol dependence was observed. Unfortunately none of the other studies
performed a gender specific analysis. In the latter study age and gender of cases and controls
were not matched. To correct their results for potential gender and age effects, they performed
a logistic regression analysis. This revealed one haplotype (C-G-A-T-T) significantly contribut-
ing to the risk to develop alcoholism (ZHANG ET AL., 2009). The haplotype consisted of the
rs3769671 A allele that was also part of the haplotype detected more frequently in cases in the
present work.
Additionally, data from animal experiments underline the implication of the POMC gene
in alcohol dependence. Studies using ß-endorphin or µ-receptor knockout mice revealed dif-
ferences in ethanol consumption and preference, whereas knockout mice either did not self-
administer ethanol or the consumption was decreased compared to wild type mice. These ef-
fects were more pronounced in female animals (RACZ ET AL., 2008; HALL ET AL., 2001;
GHOZLAND ET AL., 2005), pointing towards a gender-specific contribution. In addition, the
stress-induced increase in plasma adrenal-corticothrophin (ACTH), another product of POMC,
was prevented by a single consumption of alcohol (DAI ET AL., 2007).
The consistent results for the two marker haplotype reported here were in line with find-
ings from two other groups reporting association of overlapping markers or haplotypes. In
addition, different mouse studies reported alterations in ethanol consumption in ß-endorphin
knockout mice and the ACTH level was influenced by alcohol consumption. Altogether these
data substantiate a role for POMC in alcoholism. As POMC-derived peptides (especially ß-
endorphin and ACTH) modulate the stress response (BILKEI-GORZO ET AL., 2008; ZHOU
ET AL., 2009), variations in these gene locus might account for individual differences in stress-
reactivity, which might in turn influence ethanol consumption and the vulnerability for relapse.
Summary and conclusion
One outcome was the successful generation of conditional Penk1 knockout mice which en-
able the cell- or tissue-specific deletion of enkephalin. The mutated Penk allele contains two
loxP sites allowing cre recombinase-mediated deletion of the coding exons. A lacZ reporter
gene resulting in ß-galactosidase expression under the enkephalin promoter after cre-mediated
recombination was also inserted. In these mice, knockout of preproenkephalin results in ß-
galactosidase activity in brain regions where enkephalin is known to be expressed. Thus, the
functionality of both genetic modifications was demonstrated.
Molecular analysis of the floxed Penk1 mice revealed a reduction in mRNA and peptide
levels. As a consequence, these mice have a slightly anxiogenic phenotype. Although this weak
phenotype has to be considered it does not impair the applicability of these mice. Because the
floxed Penk1 allele always represent the control group, phenotypes measured after tissue- or
cell-specific deletion can be attributed to the absence of enkephalin.
Successful deletion of enkephalin in the targeted brain region was demonstrated by stereo-
tactic injection of cre recombinase expressing viruses. Ongoing experiments targeting the
nucleus accumbens and the VTA will provide new insights into the role of enkephalinergic
neurons in mediating nicotine reward and reinforcement. Using this new mouse model, the
contribution of enkephalin to a wide range of opioid-mediated phenotypes can be studied. Now
brain regions involved in addiction-related behaviors or neuronal structures involved in pain
relief can be assessed in detail.
The second outcome was the identification of POMC variants contributing to human alcohol
addiction. A systematic analysis of the genomic regions coding for all three endogenous opioid
peptides was performed in two independent case-control samples. Association analysis illus-
trated the importance to replicate findings in an independent cohort to exclude potential false
positive signals. The assumed role for POMC-encoded peptides in alcohol dependence was fur-
ther substantiated by this work. Interestingly, this contribution was gender-specific. A POMC
two-marker haplotype was significantly more frequent in female cases across both samples stud-
ied. Subsequently, the role of POMC was confirmed by independent studies. The correlation
of distinct alcohol-related behaviors with proopiomelanocortion and ß-endorphin particularly
demands further studies in humans.
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Appendix
Supplier information
Applichem http://www.applichem.de/
Applied Biosystems http://www.appliedbiosystems.com/
Bachem http://www.bachem.com/
Invitrogen http://www.invitrogen.com/
Metabion http://www.metabion.com/
Merck http://www.merck.de/
New England Biolabs http://www.neb.com/
Peqlab http://www.peqlab.de/
Qiagen http://www.qiagen.com/
Roche http://www.roche.de/
Roth http://www.carl-roth.de/
Sequenom http://www.sequenom.com/
Sigma http://www.sigmaaldrich.com/
Primer
Tab. A.1: Sequence information about the primers used in the scope of thesis.
Method Primer Sequence 5’-3’
realtime PCR
beta-actin for CAC ACT GTG CCC ATC TAC GA
beta-actin rev AGT GGC CAT CTC CTG CTC GA
Penk1 for GAG AGC ACC AAC AAT GAC GAA
Penk1 rev TCT TCT GGT AGT CCA TCC ACC
Southern probe
enk2-E46h GTC CGT TTG AGG GTG TTG TT
enk2-5’S-1r TGA CGC AGG CCC TAC GCC AA
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Databases
Ensembl genome browser http://www.ensembl.org/index.html
HapMap project http://hapmap.ncbi.nlm.nih.gov/
PubMed http://www.ncbi.nlm.nih.gov/sites/entrez
UCSC genome browser http://genome.ucsc.edu/
Hardy-Weinberg equilibrium
Tab. A.2: P-values for Hardy-Weinberg equilibrium in the German Sample.
Gene Marker P HWE (controls) P HWE (cases)
PENK rs12545109 0.387 0.593
PENK rs2576581 0.938 0.062
PENK rs12548084 0.1 0.361
PENK rs2670029 0.663 0.423
POMC rs2164808 0.691 0.225
POMC rs7589318 0.32 0.083
POMC rs1866146 0.079 0.353
POMC rs6713532 0.142 0.428
POMC rs934778 0.703 0.46
POMC rs3769671 0.285 0.769
POMC rs6545976 0.597 0.503
POMC rs6719226 0.176 0.502
POMC rs874401 0.35 0.492
PDYN rs6112177 0.811 0.692
PDYN rs6045761 0.235 0.083
PDYN rs6045824 0.111 0.365
PDYN rs6035235 0.091 0.289
PDYN rs6045733 0.087 0.439
PDYN rs6045784 0.075 0.643
PDYN rs2235749 0.111 0.296
PDYN rs910080 0.286 0.22
PDYN rs10485703 0.075 0.243
PDYN rs6045819 0.057 0.085
PDYN rs6035222 0.213 0.243
PDYN rs12480838 1.000 0.496
PDYN rs2235751 0.779 0.234
PDYN rs3830064 0.629 0.95
PDYN rs7272891 0.86 0.093
PDYN rs10854244 0.453 0.296
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Tab. A.3: P-values for Hardy-Weinberg equilibrium in the Swedish Sample.
Gene marker P HWE (controls) P HWE (cases)
PENK rs12545109 0.665 0.233
PENK rs2576581 0.869 0.157
PENK rs12548084 0.845 0.867
PENK rs2670029 0.779 0.081
POMC rs2164808 0.044 0.494
POMC rs7589318 0.316 0.347
POMC rs1866146 0.191 0.448
POMC rs6713532 0.821 0.683
POMC rs934778 0.068 0.102
POMC rs3769671 0.465 0.469
POMC rs6545976 0.267 0.482
POMC rs6719226 0.265 0.482
POMC rs874401 0.492 0.529
PDYN rs6112177 0.573 0.8
PDYN rs6045761 0.759 0.92
PDYN rs6045824 0.95 1
PDYN rs6035235 0.775 0.265
PDYN rs6045733 0.013 0.703
PDYN rs6045784 0.877 0.956
PDYN rs2235749 0.24 0.45
PDYN rs910080 0.38 0.546
PDYN rs10485703 0.877 0.956
PDYN rs6045819 0.699 0.818
PDYN rs6035222 0.137 0.541
PDYN rs12480838 0.639 0.538
PDYN rs2235751 0.158 1
PDYN rs3830064 0.528 0.312
PDYN rs7272891 0.253 0.417
PDYN rs10854244 0.286 0.584
Bibliography
Ahn, B. Y. and Livingston, D. M. (1986). Mitotic gene conversion lengths, coconversion pat-
terns, and the incidence of reciprocal recombination in a saccharomyces cerevisiae plasmid
system. Mol Cell Biol, 6(11):3685–93.
Akil, H., Meng, F., Devine, D., and Watson, S. (1997). Molecular and neuroanatomical proper-
ties of the endogenous opioid system: Implications for treatment of opiate addiction. Semi-
nars in Neuroscience, 9(3–4):70–83.
Akil, H., Watson, S. J., Young, E., Lewis, M. E., Khachaturian, H., and Walker, J. M. (1984).
Endogenous opioids: biology and function. Annu Rev Neurosci, 7:223–55.
Altshuler, H., Phillips, P., and Feinhandler, D. (1980). Alteration of ethanol self-administration
by naltrexone. Life Sci, 26(9):679–88.
Arias, A., Feinn, R., and Kranzler, H. (2006). Association of an asn40asp (a118g) polymor-
phism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug
Alcohol Depend, 83(3):262–8.
Armitage, P. (1955). Tests for linear trends in proportions and frequencies. Biometrics,
11(3):375–386.
Armitage, P. (1966). The chi-square test for heterogeneity of proportions, after adjustment for
stratification. Journal of the Royal Statistical Society. Series B (Methodological), 28(1):150–
163.
Barrett, J. C., Fry, B., Maller, J., and Daly, M. J. (2005). Haploview: analysis and visualization
of ld and haplotype maps. Bioinformatics, 21(2):263–5.
Becker, T. and Knapp, M. (2004). Maximum-likelihood estimation of haplotype frequencies in
nuclear families. Genet Epidemiol, 27(1):21–32.
Bergen, A., Kokoszka, J., Peterson, R., Long, J., Virkkunen, M., Linnoila, M., and Goldman,
D. (1997). Mu opioid receptor gene variants: lack of association with alcohol dependence.
Mol Psychiatry, 2(6):490–4.
Berrendero, F., Kieffer, B., and Maldonado, R. (2002). Attenuation of nicotine-induced
antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice.
J Neurosci, 22(24):10935–40.
Berrendero, F., Mendizabal, V., Robledo, P., Galeote, L., Bilkei-Gorzo, A., Zimmer, A., and
Maldonado, R. (2005). Nicotine-induced antinociception, rewarding effects, and physical de-
79
BIBLIOGRAPHY 80
pendence are decreased in mice lacking the preproenkephalin gene. J Neurosci, 25(5):1103–
12.
Bilkei-Gorzó, A., Otto, M., and Zimmer, A. (2008). Environmental modulation of anxiety-
related neuronal activity and behaviors. Behav Brain Res, 186(2):289–92.
Bilkei-Gorzo, A., Racz, I., Michel, K., Mauer, D., Zimmer, A., Klingmuller, D., and Zimmer,
A. (2008). Control of hormonal stress reactivity by the endogenous opioid system. Psy-
choneuroendocrinology, 33(4):425–36.
Bilkei-Gorzo, A., Racz, I., Michel, K., Zimmer, A., Klingmuller, D., and Zimmer, A. (2004).
Behavioral phenotype of pre-proenkephalin-deficient mice on diverse congenic backgrounds.
Psychopharmacology (Berl), 176(3-4):343–52.
Blednov, Y., Walker, D., Martinez, M., and Harris, R. (2006). Reduced alcohol consumption in
mice lacking preprodynorphin. Alcohol, 40(2):73–86.
Branch, A. D., Unterwald, E. M., Lee, S. E., and Kreek, M. J. (1992). Quantitation of pre-
proenkephalin mrna levels in brain regions from male fischer rats following chronic cocaine
treatment using a recently developed solution hybridization assay. Brain Res Mol Brain Res,
14(3):231–8.
Burger, C., Nash, K., and Mandel, R. J. (2005). Recombinant adeno-associated viral vectors in
the nervous system. Hum Gene Ther, 16(7):781–91.
Camí, J. and Farré, M. (2003). Drug addiction. N Engl J Med, 349(10):975–86.
Capecchi, M. R. (1989). Altering the genome by homologous recombination. Science,
244(4910):1288–92.
Chan, R., McBride, A., Thomasson, H., Ykenney, A., and Crabb, D. (1994). Allele frequen-
cies of the preproenkephalin a (penk) gene ca repeat in asians, african-americans, and cau-
casians: lack of evidence for different allele frequencies in alcoholics. Alcohol Clin Exp Res,
18(3):533–5.
Chen, J.-M., Férec, C., and Cooper, D. N. (2006). A systematic analysis of disease-associated
variants in the 3’ regulatory regions of human protein-coding genes ii: the importance of mrna
secondary structure in assessing the functionality of 3’ utr variants. Hum Genet, 120(3):301–
33.
Chong, R., Oswald, L., Yang, X., Uhart, M., Lin, P., and Wand, G. (2006). The micro-opioid
receptor polymorphism a118g predicts cortisol responses to naloxone and stress. Neuropsy-
chopharmacology, 31(1):204–11.
Ciccocioppo, R., Martin-Fardon, R., and Weiss, F. (2002). Effect of selective blockade of mu(1)
or delta opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated
stimuli in rats. Neuropsychopharmacology, 27(3):391–9.
Clarke, S., Zimmer, A., Zimmer, A., Hill, R., and Kitchen, I. (2003). Region selective up-
regulation of micro-, delta- and kappa-opioid receptors but not opioid receptor-like 1 recep-
tors in the brains of enkephalin and dynorphin knockout mice. Neuroscience, 122(2):479–89.
Colhoun, H. M., McKeigue, P. M., and Smith, G. D. (2003). Problems of reporting genetic
BIBLIOGRAPHY 81
associations with complex outcomes. Lancet, 361(9360):865–72.
Contet, C., Kieffer, B., and Befort, K. (2004). Mu opioid receptor: a gateway to drug addiction.
Curr Opin Neurobiol, 14(3):370–8.
Crabbe, J. (2002). Alcohol and genetics: new models. Am J Med Genet, 114(8):969–74.
Crabbe, J., Metten, P., Ponomarev, I., Prescott, C., and Wahlsten, D. (2006). Effects of ge-
netic and procedural variation on measurement of alcohol sensitivity in mouse inbred strains.
Behav Genet, 36(4):536–52.
Dai, X., Thavundayil, J., Santella, S., and Gianoulakis, C. (2007). Response of the hpa-axis
to alcohol and stress as a function of alcohol dependence and family history of alcoholism.
Psychoneuroendocrinology, 32(3):293–305.
Day, R., Lazure, C., Basak, A., Boudreault, A., Limperis, P., Dong, W., and Lindberg, I. (1998).
Prodynorphin processing by proprotein convertase 2. cleavage at single basic residues and
enhanced processing in the presence of carboxypeptidase activity. J Biol Chem, 273(2):829–
36.
Di Chiara, G. (2002). Nucleus accumbens shell and core dopamine: differential role in behavior
and addiction. Behav Brain Res, 137(1-2):75–114.
Dooley, T. P., Miranda, M., Jones, N. C., and DePamphilis, M. L. (1989). Transactivation of
the adenovirus eiia promoter in the absence of adenovirus e1a protein is restricted to mouse
oocytes and preimplantation embryos. Development, 107(4):945–56.
Drews, E. and Zimmer, A. (2009). Modulation of alcohol and nicotine responses through the
endogenous opioid system. Prog Neurobiol. in press.
Eiden, L., Giraud, P., Dave, J., Hotchkiss, A., and Affolter, H. (1984). Nicotinic receptor
stimulation activates enkephalin release and biosynthesis in adrenal chromaffin cells. Nature,
312(5995):661–3.
Feltenstein, M. and See, R. (2008). The neurocircuitry of addiction: an overview. Br J Phar-
macol, 154(2):261–74.
Franke, P., Nothen, M., Wang, T., Neidt, H., Knapp, M., Lichtermann, D., Weiffenbach, O.,
Mayer, P., Höllt, V., Propping, P., and Maier, W. (1999). Human delta-opioid receptor gene
and susceptibility to heroin and alcohol dependence. Am J Med Genet, 88(5):462–4.
Franke, P., Wang, T., Nothen, M., Knapp, M., Neidt, H., Albrecht, S., Jahnes, E., Propping,
P., and Maier, W. (2001). Nonreplication of association between mu-opioid-receptor gene
(oprm1) a118g polymorphism and substance dependence. Am J Med Genet, 105(1):114–9.
Freund, T. F., Katona, I., and Piomelli, D. (2003). Role of endogenous cannabinoids in synaptic
signaling. Physiological Reviews, 83(3):1017–66.
Froehlich, J., Harts, J., Lumeng, L., and Li, T. (1990). Naloxone attenuates voluntary ethanol
intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav,
35(2):385–90.
Gabriel, S. B., Schaffner, S. F., Nguyen, H., Moore, J. M., Roy, J., Blumenstiel, B., Higgins,
J., DeFelice, M., Lochner, A., Faggart, M., Liu-Cordero, S. N., Rotimi, C., Adeyemo, A.,
BIBLIOGRAPHY 82
Cooper, R., Ward, R., Lander, E. S., Daly, M. J., and Altshuler, D. (2002). The structure of
haplotype blocks in the human genome. Science, 296(5576):2225–9.
Galeote, L., Berrendero, F., Bura, S. A., Zimmer, A., and Maldonado, R. (2008). Prodynor-
phin gene disruption increases the sensitivity to nicotine self-administration in mice. Int J
Neuropsychopharmacol, pages 1–11.
Garzón, M. and Pickel, V. M. (2004). Ultrastructural localization of leu5-enkephalin im-
munoreactivity in mesocortical neurons and their input terminals in rat ventral tegmental
area. Synapse, 52(1):38–52.
Gaveriaux-Ruff, C. and Kieffer, B. (2002). Opioid receptor genes inactivated in mice: the
highlights. Neuropeptides, 36(2-3):62–71.
Geijer, T., Jönsson, E., Neiman, J., Gyllander, A., Sedvall, G., Rydberg, U., and Terenius, L.
(1997). Prodynorphin allelic distribution in scandinavian chronic alcoholics. Alcohol Clin
Exp Res, 21(7):1333–6.
Gelernter, J., Kranzler, H., and Cubells, J. (1999). Genetics of two mu opioid receptor gene
(oprm1) exon i polymorphisms: population studies, and allele frequencies in alcohol- and
drug-dependent subjects. Mol Psychiatry, 4(5):476–83.
Ghozland, S., Chu, K., Kieffer, B., and Roberts, A. (2005). Lack of stimulant and anxiolytic-like
effects of ethanol and accelerated development of ethanol dependence in mu-opioid receptor
knockout mice. Neuropharmacology, 49(4):493–501.
Ghozland, S., Matthes, H. W. D., Simonin, F., Filliol, D., Kieffer, B. L., and Maldonado, R.
(2002). Motivational effects of cannabinoids are mediated by mu-opioid and kappa-opioid
receptors. J Neurosci, 22(3):1146–54.
Gianoulakis, C. (1990). Characterization of the effects of acute ethanol administration on the
release of beta-endorphin peptides by the rat hypothalamus. Eur J Pharmacol, 180(1):21–9.
Gianoulakis, C. (2001). Influence of the endogenous opioid system on high alcohol consump-
tion and genetic predisposition to alcoholism. J Psychiatry Neurosci, 26(4):304–18.
Gianoulakis, C. (2004). Endogenous opioids and addiction to alcohol and other drugs of abuse.
Curr Top Med Chem, 4(1):39–50.
Grahame, N., Mosemiller, A., Low, M., and Froehlich, J. (2000). Naltrexone and alcohol
drinking in mice lacking beta-endorphin by site-directed mutagenesis. Pharmacol Biochem
Behav, 67(4):759–66.
Grisel, J., Mogil, J., Grahame, N., Rubinstein, M., Belknap, J., Crabbe, J., and Low, M. (1999).
Ethanol oral self-administration is increased in mutant mice with decreased beta-endorphin
expression. Brain Res, 835(1):62–7.
Gulya, K., Orpana, A., Sikela, J., and Hoffman, P. (1993). Prodynorphin and vasopressin mrna
levels are differentially affected by chronic ethanol ingestion in the mouse. Brain Res Mol
Brain Res, 20(1-2):1–8.
Hall, F., Sora, I., and Uhl, G. (2001). Ethanol consumption and reward are decreased in mu-
opiate receptor knockout mice. Psychopharmacology (Berl), 154(1):43–9.
BIBLIOGRAPHY 83
Hayward, M., Hansen, S., Pintar, J., and Low, M. (2004). Operant self-administration of
ethanol in c57bl/6 mice lacking beta-endorphin and enkephalin. Pharmacol Biochem Be-
hav, 79(1):171–81.
Hein, I., Lehner, A., Rieck, P., Klein, K., Brandl, E., and Wagner, M. (2001). Comparison of
different approaches to quantify staphylococcus aureus cells by real-time quantitative pcr and
application of this technique for examination of cheese. Appl Environ Microbiol, 67(7):3122–
6.
Hlavaty, J., Portsmouth, D., Stracke, A., Salmons, B., Günzburg, W. H., and Renner, M. (2004).
Effects of sequences of prokaryotic origin on titer and transgene expression in retroviral
vectors. Virology, 330(1):351–60.
Hoefgen, B., Schulze, T. G., Ohlraun, S., vonWiddern, O., Höfels, S., Gross, M., Heidmann, V.,
Kovalenko, S., Eckermann, A., Kölsch, H., Metten, M., Zobel, A., Becker, T., Nöthen, M. M.,
Propping, P., Heun, R., Maier, W., and Rietschel, M. (2005). The power of sample size and
homogenous sampling: association between the 5-httlpr serotonin transporter polymorphism
and major depressive disorder. Biol Psychiatry, 57(3):247–51.
Höllt, V. and Horn, G. (1992). Effect of nicotine on mrna levels encoding opioid peptides,
vasopressin and alpha 3 nicotinic receptor subunit in the rat. Clin Investig, 70(3-4):224–31.
Houdi, A., Pierzchala, K., Marson, L., Palkovits, M., and Loon, G. V. (1991). Nicotine-
induced alteration in tyr-gly-gly and met-enkephalin in discrete brain nuclei reflects altered
enkephalin neuron activity. Peptides, 12(1):161–6.
Howard, D. B., Powers, K., Wang, Y., and Harvey, B. K. (2008). Tropism and toxicity of
adeno-associated viral vector serotypes 1, 2, 5, 6, 7, 8, and 9 in rat neurons and glia in vitro.
Virology, 372(1):24–34.
Hyytia, P. and Kiianmaa, K. (2001). Suppression of ethanol responding by centrally adminis-
tered ctop and naltrindole in aa and wistar rats. Alcohol Clin Exp Res, 25(1):25–33.
Isola, R., Zhang, H., Tejwani, G., Neff, N., and Hadjiconstantinou, M. (2009). Acute nicotine
changes dynorphin and prodynorphin mrna in the striatum. Psychopharmacology (Berl),
201(4):507–16.
June, H. (2002). Preclinical models to evaluate potential pharmacotherapeutic agents in treating
alcoholism and studying the neuropharmacological bases of ethanol-seeking behaviors in
rats. Curr Protoc Neurosci, Chapter 9.
Keyser, R., van der Merwe, L., Venter, M., Kinnear, C., Warnich, L., Carr, J., and Bardien, S.
(2009). Identification of a novel functional deletion variant in the 5’-utr of the dj-1 gene.
BMC Med Genet, 10(1):105.
Kieffer, B. and Gaveriaux-Ruff, C. (2002). Exploring the opioid system by gene knockout.
Prog Neurobiol, 66(5):285–306.
Kiguchi, N., Maeda, T., Tsuruga, M., Yamamoto, A., Yamamoto, C., Ozaki, M., and Kishioka,
S. (2008). Involvement of spinal met-enkephalin in nicotine-induced antinociception in mice.
Brain Res, 1189:70–7.
BIBLIOGRAPHY 84
Kim, S., Kim, C., Choi, S., Jae, Y., Lee, H., Son, B., Kim, J., Choi, Y., Kim, H., Kim, S., and
Oslin, D. (2009). A micro opioid receptor gene polymorphism (a118g) and naltrexone treat-
ment response in adherent korean alcohol-dependent patients. Psychopharmacology (Berl),
201(4):611–8.
Koenig, H. and Olive, M. (2002). Ethanol consumption patterns and conditioned place prefer-
ence in mice lacking preproenkephalin. Neurosci Lett, 325(2):75–8.
König, M., Zimmer, A., Steiner, H., Holmes, P., Crawley, J., Brownstein, M., and Zimmer,
A. (1996). Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin.
Nature, 383:535–8.
Koob, G. (1992). Drugs of abuse: anatomy, pharmacology and function of reward pathways.
Trends Pharmacol Sci, 13(5):177–84.
Koob, G., Roberts, A., Schulteis, G., Parsons, L., Heyser, C., Hyytia, P., Merlo-Pich, E., and
Weiss, F. (1998). Neurocircuitry targets in ethanol reward and dependence. Alcohol Clin Exp
Res, 22(1):3–9.
Koob, G. F. and Le Moal, M. (2005). Plasticity of reward neurocircuitry and the ’dark side’ of
drug addiction. Nat Neurosci, 8(11):1442–4.
Koob, G. F. and Le Moal, M. (2008). Addiction and the brain antireward system. Annual review
of psychology, 59:29–53.
Kovacs, K., Szakall, I., O’Brien, D., Wang, R., Vinod, K., Saito, M., Simonin, F., Kieffer,
B., and Vadasz, C. (2005). Decreased oral self-administration of alcohol in kappa-opioid
receptor knock-out mice. Alcohol Clin Exp Res, 29(5):730–8.
Kreek, M., LaForge, K., and Butelman, E. (2002). Pharmacotherapy of addictions. Nat Rev
Drug Discov, 1(9):710–26.
Krishnan-Sarin, S., Jing, S., Kurtz, D., Zweifel, M., Portoghese, P., Li, T., and Froehlich, J.
(1995a). The delta opioid receptor antagonist naltrindole attenuates both alcohol and sac-
charin intake in rats selectively bred for alcohol preference. Psychopharmacology (Berl),
120(2):177–85.
Krishnan-Sarin, S., Portoghese, P., Li, T., and Froehlich, J. (1995b). The delta 2-opioid receptor
antagonist naltriben selectively attenuates alcohol intake in rats bred for alcohol preference.
Pharmacol Biochem Behav, 52(1):153–9.
Kumar, T. R., Larson, M., Wang, H., McDermott, J., and Bronshteyn, I. (2009). Transgenic
mouse technology: principles and methods. Methods Mol Biol, 590:335–62.
Lakso, M., Pichel, J. G., Gorman, J. R., Sauer, B., Okamoto, Y., Lee, E., Alt, F. W., and
Westphal, H. (1996). Efficient in vivo manipulation of mouse genomic sequences at the
zygote stage. Proc Natl Acad Sci USA, 93(12):5860–5.
Lallemand, Y., Luria, V., Haffner-Krausz, R., and Lonai, P. (1998). Maternally expressed pgk-
cre transgene as a tool for early and uniform activation of the cre site-specific recombinase.
Transgenic Res, 7(2):105–12.
Li, X., Li, T., and Froehlich, J. (1998). Enhanced sensitivity of the nucleus accumbens
BIBLIOGRAPHY 85
proenkephalin system to alcohol in rats selectively bred for alcohol preference. Brain Res,
794(1):35–47.
Lindholm, S., Werme, M., Brene, S., and Franck, J. (2001). The selective kappa-opioid receptor
agonist u50,488h attenuates voluntary ethanol intake in the rat. Behav Brain Res, 120(2):137–
46.
Livak, K. J. and Schmittgen, T. D. (2001). Analysis of relative gene expression data using
real-time quantitative pcr and the 2(-delta delta c(t)) method. Methods, 25(4):402–8.
Livett, B., Dean, D., Whelan, L., Udenfriend, S., and Rossier, J. (1981). Co-release of
enkephalin and catecholamines from cultured adrenal chromaffin cells. Nature, 289:317–
9.
Loh, W., Fann, C., Chang, Y., Chang, C., and Cheng, A. (2004). Endogenous opioid receptor
genes and alcohol dependence among taiwanese han. Alcohol Clin Exp Res, 28(1):15–9.
MacArthur, L., Iacangelo, A., Hsu, C., and Eiden, L. (1992). Enkephalin biosynthesis is coupled
to secretory activity via transcription of the proenkephalin a gene. J Physiol Paris, 86(1-
3):89–98.
Mansour, A., Hoversten, M. T., Taylor, L. P., Watson, S. J., and Akil, H. (1995). The cloned
mu, delta and kappa receptors and their endogenous ligands: evidence for two opioid peptide
recognition cores. Brain Res, 700(1-2):89–98.
Martín-García, E., Barbano, M. F., Galeote, L., and Maldonado, R. (2009). New operant model
of nicotine-seeking behaviour in mice. Int J Neuropsychopharmacol, 12(3):343–56.
Matthes, H. W., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K.,
Dierich, A., Meur, M. L., Dollé, P., Tzavara, E., Hanoune, J., Roques, B. P., and Kieffer,
B. L. (1996). Loss of morphine-induced analgesia, reward effect and withdrawal symptoms
in mice lacking the mu-opioid-receptor gene. Nature, 383(6603):819–23.
Maxwell, S. E., Kelley, K., and Rausch, J. R. (2008). Sample size planning for statistical power
and accuracy in parameter estimation. Annual review of psychology, 59:537–63.
Meng, Z., Zaykin, D. V., Xu, C.-F., Wagner, M., and Ehm, M. G. (2003). Selection of genetic
markers for association analyses, using linkage disequilibrium and haplotypes. Am J Hum
Genet, 73(1):115–30.
Milner, T. A., Pickel, V. M., and Reis, D. J. (1989). Ultrastructural basis for interactions between
central opioids and catecholamines. i. rostral ventrolateral medulla. J Neurosci, 9(6):2114–
30.
Monory, K., Blaudzun, H., Massa, F., Kaiser, N., Lemberger, T., Schütz, G., Wotjak, C. T.,
Lutz, B., and Marsicano, G. (2007). Genetic dissection of behavioural and autonomic effects
of delta(9)-tetrahydrocannabinol in mice. PLoS Biol, 5(10):e269.
Monory, K., Massa, F., Egertová, M., Eder, M., Blaudzun, H., Westenbroek, R., Kelsch, W.,
Jacob, W., Marsch, R., Ekker, M., Long, J., Rubenstein, J. L., Goebbels, S., Nave, K.-A.,
During, M., Klugmann, M., Wölfel, B., Dodt, H.-U., Zieglgänsberger, W., Wotjak, C. T.,
Mackie, K., Elphick, M. R., Marsicano, G., and Lutz, B. (2006). The endocannabinoid
BIBLIOGRAPHY 86
system controls key epileptogenic circuits in the hippocampus. Neuron, 51(4):455–66.
Myers, R., Borg, S., and Mossberg, R. (1986). Antagonism by naltrexone of voluntary alcohol
selection in the chronically drinking macaque monkey. Alcohol, 3(6):383–8.
Nestler, E. J. (2004a). Historical review: Molecular and cellular mechanisms of opiate and
cocaine addiction. Trends Pharmacol Sci, 25(4):210–8.
Nestler, E. J. (2004b). Molecular mechanisms of drug addiction. Neuropharmacology, 47:24–
32.
Nylander, I., Hyytia, P., Forsander, O., and Terenius, L. (1994). Differences between alcohol-
preferring (aa) and alcohol-avoiding (ana) rats in the prodynorphin and proenkephalin sys-
tems. Alcohol Clin Exp Res, 18(5):1272–9.
Olive, M. F., Mehmert, K. K., Koenig, H. N., Camarini, R., Kim, J. A., Nannini, M. A., Ou,
C. J., and Hodge, C. W. (2003). A role for corticotropin releasing factor (crf) in ethanol
consumption, sensitivity, and reward as revealed by crf-deficient mice. Psychopharmacology
(Berl), 165(2):181–7.
Paxinos, G. and Franklin, K. B. J. (2001). The Mouse Brain in Stereotaxic Coordinates. ELSE-
VIER Academic Press.
Pert, C. B. and Snyder, S. H. (1973). Opiate receptor: demonstration in nervous tissue. Science,
179(77):1011–4.
Racz, I., Bilkei-Gorzo, A., Toth, Z., Michel, K., Palkovits, M., and Zimmer, A. (2003). A
critical role for the cannabinoid cb1 receptors in alcohol dependence and stress-stimulated
ethanol drinking. J Neurosci, 23(6):2453–8.
Racz, I., Schürmann, B., Karpushova, A., Reuter, M., Cichon, S., Montag, C., Furst, R., Schutz,
C., Franke, P., Strohmaier, J., Wienker, T., Terenius, L., Osby, U., Gunnar, A., Maier, W.,
Bilkei-Gorzo, A., Nothen, M., and Zimmer, A. (2008). The opioid peptides enkephalin and
beta-endorphin in alcohol dependence. Biol Psychiatry, 64:989–997.
Rasmussen, D., Bryant, C., Boldt, B., Colasurdo, E., Levin, N., andWilkinson, C. (1998). Acute
alcohol effects on opiomelanocortinergic regulation. Alcohol Clin Exp Res, 22(4):789–801.
Ray, R., Schnoll, R. A., and Lerman, C. (2009). Nicotine dependence: biology, behavior, and
treatment. Annu Rev Med, 60:247–60.
Reich, T., Edenberg, H. J., Goate, A., Williams, J. T., Rice, J. P., Eerdewegh, P. V., Foroud,
T., Hesselbrock, V., Schuckit, M. A., Bucholz, K., Porjesz, B., Li, T. K., Conneally, P. M.,
Nurnberger, J. I., Tischfield, J. A., Crowe, R. R., Cloninger, C. R., Wu, W., Shears, S., Carr,
K., Crose, C., Willig, C., and Begleiter, H. (1998). Genome-wide search for genes affecting
the risk for alcohol dependence. Am J Med Genet, 81(3):207–15.
Reich, T., Hinrichs, A., Culverhouse, R., and Bierut, L. (1999). Genetic studies of alcoholism
and substance dependence. Am J Hum Genet, 65(3):599–605.
Rezayof, A., Nazari-Serenjeh, F., Zarrindast, M., Sepehri, H., and Delphi, L. (2007). Morphine-
induced place preference: involvement of cholinergic receptors of the ventral tegmental area.
Eur J Pharmacol, 562(1-2):92–102.
BIBLIOGRAPHY 87
Roberts, A., Gold, L., Polis, I., McDonald, J., Filliol, D., Kieffer, B., and Koob, G. (2001).
Increased ethanol self-administration in delta-opioid receptor knockout mice. Alcohol Clin
Exp Res, 25(9):1249–56.
Roberts, A., McDonald, J., Heyser, C., Kieffer, B., Matthes, H., Koob, G., and Gold, L. (2000).
mu-opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther,
293(3):1002–8.
Rommelspacher, H., Smolka, M., Schmidt, L., Samochowiec, J., and Hoehe, M. (2001).
Genetic analysis of the mu-opioid receptor in alcohol-dependent individuals. Alcohol,
24(2):129–35.
Roth-Deri, I., Green-Sadan, T., and Yadid, G. (2008). Beta-endorphin and drug-induced reward
and reinforcement. Prog Neurobiol, 86(1):1–21.
Sambrook, J. and Russell, D. W. (2001). Molecular cloning: a laboratory manual. Cold Spring
Harbor Laboratory Press.
Sanchis-Segura, C. and Spanagel, R. (2006). Behavioural assessment of drug reinforcement
and addictive features in rodents: an overview. Addict Biol, 11(1):2–38.
Sandi, C., Borrell, J., and Guaza, C. (1988). Involvement of kappa type opioids on ethanol
drinking. Life Sci, 42(10):1067–75.
Schaid, D. J. (2004). Evaluating associations of haplotypes with traits. Genet Epidemiol,
27(4):348–64.
Schulz, R., Wuster, M., Duka, T., and Herz, A. (1980). Acute and chronic ethanol treatment
changes endorphin levels in brain and pituitary. Psychopharmacology (Berl), 68(3):221–7.
Schürmann, B. (2004). Untersuchungen am endogenen Opioidsystem. Master’s thesis, Univer-
sity of Bonn, Germany.
Seizinger, B., Bovermann, K., Maysinger, D., Höllt, V., and Herz, A. (1983). Differential effects
of acute and chronic ethanol treatment on particular opioid peptide systems in discrete regions
of rat brain and pituitary. Pharmacol Biochem Behav, 18:361–9.
Soria, G., Mendizábal, V., Touriño, C., Robledo, P., Ledent, C., Parmentier, M., Maldon-
ado, R., and Valverde, O. (2005). Lack of cb1 cannabinoid receptor impairs cocaine self-
administration. Neuropsychopharmacology, 30(9):1670–80.
Spanagel, R., Herz, A., and Shippenberg, T. (1992). Opposing tonically active endogenous
opioid systems modulate the mesolimbic dopaminergic pathway. Proc Natl Acad Sci U S A,
89(6):2046–50.
Taymans, J.-M., Vandenberghe, L. H., Haute, C. V. D., Thiry, I., Deroose, C. M., Mortelmans,
L., Wilson, J. M., Debyser, Z., and Baekelandt, V. (2007). Comparative analysis of adeno-
associated viral vector serotypes 1, 2, 5, 7, and 8 in mouse brain. Hum Gene Ther, 18(3):195–
206.
Tian, B., Rentz, S. S., Gorman, G. S., Rogers, T., and Page, J. G. (2004). Comparison of real-
time pcr assay methods in detection and quantitation of beta-actin genes inmouse tissues.
Preclinica, 2(3):214–220.
BIBLIOGRAPHY 88
Town, T., Abdullah, L., Crawford, F., Schinka, J., Ordorica, P., Francis, E., Hughes, P., Duara,
R., and Mullan, M. (1999). Association of a functional mu-opioid receptor allele (+118a)
with alcohol dependency. Am J Med Genet, 88(5):458–61.
Trigo, J. M., Zimmer, A., and Maldonado, R. (2009). Nicotine anxiogenic and rewarding effects
are decreased in mice lacking beta-endorphin. Neuropharmacology, 56(8):1147–53.
Vadasz, C., Saito, M., Gyetvai, B., Mikics, E., and Vadasz, C. (2000). Scanning of five chro-
mosomes for alcohol consumption loci. Alcohol, 22(1):25–34.
Valera, A., Perales, J. C., Hatzoglou, M., and Bosch, F. (1994). Expression of the neomycin-
resistance (neo) gene induces alterations in gene expression and metabolism. Hum Gene
Ther, 5(4):449–56.
Valverde, O., Maldonado, R., Valjent, E., Zimmer, A. M., and Zimmer, A. (2000). Cannabi-
noid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. J Neurosci,
20(24):9284–9.
Vengeliene, V., Bilbao, A., Molander, A., and Spanagel, R. (2008). Neuropharmacology of
alcohol addiction. Br J Pharmacol, 154(2):299–315.
von Zastrow, M., Svingos, A., Haberstock-Debic, H., and Evans, C. (2003). Regulated endocy-
tosis of opioid receptors: cellular mechanisms and proposed roles in physiological adaptation
to opiate drugs. Curr Opin Neurobiol, 13(3):348–53.
Voss, A. K., Thomas, T., and Gruss, P. (1998). Efficiency assessment of the gene trap approach.
Dev Dyn, 212(2):171–80.
Waele, J. D., Papachristou, D., and Gianoulakis, C. (1992). The alcohol-preferring c57bl/6 mice
present an enhanced sensitivity of the hypothalamic beta-endorphin system to ethanol than
the alcohol-avoiding dba/2 mice. J Pharmacol Exp Ther, 261(2):788–94.
Walker, B. and Koob, G. (2008). Pharmacological evidence for a motivational role of kappa-
opioid systems in ethanol dependence. Neuropsychopharmacology, 33(3):643–52.
Wand, G., McCaul, M., Yang, X., Reynolds, J., Gotjen, D., Lee, S., and Ali, A. (2002). The
mu-opioid receptor gene polymorphism (a118g) alters hpa axis activation induced by opioid
receptor blockade. Neuropsychopharmacology, 26(1):106–14.
Wang, J., Pitarque, M., and Ingelman-Sundberg, M. (2006). 3’-utr polymorphism in the human
cyp2a6 gene affects mrna stability and enzyme expression. Biochem Biophys Res Commun,
340(2):491–7.
Wang, X., Wang, G., Lemos, J., and Treistman, S. (1994). Ethanol directly modulates gat-
ing of a dihydropyridine-sensitive ca2+ channel in neurohypophysial terminals. J Neurosci,
14(9):5453–60.
Weisinger, G. (1995). The transcriptional regulation of the preproenkephalin gene. Biochem J,
307 ( Pt 3):617–29.
Weisinger, G., DeCristofaro, J. D., and LaGamma, E. F. (1992). Tissue- and treatment-specific
usage of multiple preproenkephalin transcriptional start sites. J Biol Chem, 267(7):4508–12.
Weiss, F., Mitchiner, M., Bloom, F., and Koob, G. (1990). Free-choice responding for ethanol
BIBLIOGRAPHY 89
versus water in alcohol preferring (p) and unselected wistar rats is differentially modified by
naloxone, bromocriptine, and methysergide. Psychopharmacology (Berl), 101(2):178–86.
Wewers, M., Tejwani, G., and Anderson, J. (1994). Plasma nicotine, plasma beta-endorphin
and mood states during periods of chronic smoking, abstinence and nicotine replacement.
Psychopharmacology (Berl), 116(1):98–102.
Williams, J. T., Christie, M. J., and Manzoni, O. (2001). Cellular and synaptic adaptations
mediating opioid dependence. Physiological Reviews, 81(1):299–343.
Xuei, X., Dick, D., Flury-Wetherill, L., Tian, H., Agrawal, A., Bierut, L., Goate, A., Bucholz,
K., Schuckit, M., Nurnberger, J., Tischfield, J., Kuperman, S., Porjesz, B., Begleiter, H.,
Foroud, T., and Edenberg, H. (2006). Association of the kappa-opioid system with alcohol
dependence. Mol Psychiatry, 11(11):1016–24.
Xuei, X., Flury-Wetherill, L., Bierut, L., Dick, D., Nurnberger, J., Foroud, T., and Edenberg, H.
(2007). The opioid system in alcohol and drug dependence: Family-based association study.
Am J Med Genet B Neuropsychiatr Genet, 144(B):877–884.
Yoshikawa, K., Williams, C., and Sabol, S. L. (1984). Rat brain preproenkephalin mrna. cdna
cloning, primary structure, and distribution in the central nervous system. J Biol Chem,
259(22):14301–8.
Yuferov, V., Ji, F., Nielsen, D. A., Levran, O., Ho, A., Morgello, S., Shi, R., Ott, J., and Kreek,
M. J. (2009). A functional haplotype implicated in vulnerability to develop cocaine depen-
dence is associated with reduced pdyn expression in human brain. Neuropsychopharmacol-
ogy, 34(5):1185–97.
Zamir, N., Weber, E., Palkovits, M., and Brownstein, M. (1984). Differential processing of
prodynorphin and proenkephalin in specific regions of the rat brain. Proc Natl Acad Sci USA,
81(21):6886–9.
Zarrindast, M., Faraji, N., Rostami, P., Sahraei, H., and Ghoshouni, H. (2003). Cross-tolerance
between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol
Biochem Behav, 74(2):363–9.
Zarudnaya, M. I., Kolomiets, I. M., Potyahaylo, A. L., and Hovorun, D. M. (2003). Downstream
elements of mammalian pre-mrna polyadenylation signals: primary, secondary and higher-
order structures. Nucleic Acids Res, 31(5):1375–86.
Zhang, H., Kranzler, H., Yang, B., Luo, X., and Gelernter, J. (2008). The oprd1 and oprk1 loci
in alcohol or drug dependence: Oprd1 variation modulates substance dependence risk. Mol
Psychiatry, 13(5):531–43.
Zhang, H., Kranzler, H. R., Weiss, R. D., Luo, X., Brady, K. T., Anton, R. F., Farrer, L. A.,
and Gelernter, J. (2009). Pro-opiomelanocortin gene variation related to alcohol or drug
dependence: evidence and replications across family- and population-based studies. Biol
Psychiatry, 66(2):128–36.
Zhou, Y., Proudnikov, D., Yuferov, V., and Kreek, M. (2009). Drug-induced and genetic alter-
ations in stress-responsive systems: Implications for specific addictive diseases. Brain Res.
BIBLIOGRAPHY 90
in press.
Zimmer, A., Valjent, E., Konig, M., Zimmer, A. M., Robledo, P., Hahn, H., Valverde, O.,
and Maldonado, R. (2001). Absence of delta -9-tetrahydrocannabinol dysphoric effects in
dynorphin-deficient mice. J Neurosci, 21(23):9499–505.
Acknowledgement
Mein besonderer Dank gilt Herrn Prof. Dr. Andreas Zimmer für die Überlassung des The-
mas, für seinen fachlichen Rat und die fortdauernde Unterstützung während der gesamten Zeit
meiner Doktorarbeit.
Herrn Prof. Dr. Jörg Höhfeld danke ich für die Begutachtung meiner Doktorarbeit.
Ein Dankeschön auch an alle Kooperationspartner, die bereitwillig Material und Expertise zur
Verfügung gestellt haben vor allem Dr. J.M. Trigo, Prof. R. Maldonado, Dr. A. Karpushova and
Prof. Dr. M. Nöthen.
Ein großes Dankeschön an alle Mitarbeiter des Instituts für Ihre stete Hilfsbereitschaft, für
eine angenehme, unterhaltsame Arbeitsatmosphäre und natürlich Ihren fachlichen Rat. Ganz
besonders erwähnen möchte ich Dr. David M. Otte, Dr. Eva Drews, Katja Krumnack, die durch
ihre Korrekturen geholfen haben den Text zu glätten, sowie Kerstin Michel, Anne Zimmer, Dr.
Ildiko Rácz, Dr. Andras Bilkei-Gorzo für Ihre Hilfe bei der Lösung vieler kleiner oder auch
größerer Probleme. Auch Julia Woelke, Jenny Rehnelt, Öznur Yilmaz, Dr. Judith Alferink, Dr.
Xavier Miro sollen nicht unerwähnt bleiben.
Danke Z!!!!
Nicht zuletzt ein großes Dankeschön an meine Familie für Ihre Unterstützung!
91
Statutory declaration
I hereby affirm that I prepared this thesis entitled: “Endogenous opiod peptides in drug addic-
tion” entirely by myself except where otherwise stated. All text passages that are literally or
correspondingly taken from published or unpublished papers/writings are indicated as such.
All materials or services provided by other persons are equally indicated. Parts of this thesis
are published as listed:
Schürmann B, Racz I, Zimmer A (2007) Animal experimental studies on the function of the
endogenous opioid system for the controlling of drug abuse. Nervenheilkunde 26:897-901
Racz I*, Schürmann B*, Karpushova A, Reuter M, Cichon S, Montag C, Fürst R, Schütz C,
Franke PE, Strohmaier J, Wienker TF, Terenius L, Osby U, Gunnar A, Maier W, Bilkei-Gorzó
A, Nöthen M, Zimmer A (2008) The opioid peptides enkephalin and beta-endorphin in alcohol
dependence. Biol Psychiatry 64(11):989-97.
* equal contribution
Bonn, December 1st 2009
(Britta Schürmann)
93
